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ABSTRACT OF THE DISSERTATION
Tissue Damage Quantification in Alzheimer’s Disease Brain via Magnetic Resonance
Gradient Echo Plural Contrast Imaging (GEPCI)
by
Yue Zhao (赵越)
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2017
Professor Joseph Ackerman, Chair
Professor Dmitriy Yablonskiy
Alzheimer’s disease (AD) affected approximately 48 million people worldwide in 2015. Its
devastating consequences have stimulated an intense search for AD prevention and treatment.
Clinically, AD is characterized by memory deficits and progressive cognitive impairment,
leading to dementia. Over the past two to three decades, researchers have found that amyloidbeta (Aβ) plaques and neurofibrillary tau tangles occur during a long pre-symptomatic period
(preclinical stage) before the onset of clinical symptoms. As a result, identification of the
preclinical stage is essential for the initiation of prevention trials in asymptomatic individuals.
Currently, Positron Emission Tomography (PET) imaging with injected

11

radiotracers (e.g., Pittsburgh compound B, PiB or florbetapir-fluorine-18,

18

C or

18

F containing

F-AV-45) is widely

used to detect amyloid deposition in vivo and to identify this preclinical stage. However, PET
scans are time consuming (about 1 hour), require injection of a radiotracer, thus, exposing the
patient to ionizing radiation. After the preclinical stage, AD patients begin to show clinical
symptoms, referred as a very mild or mild AD group. Post-mortem studies show that neuronal
damage is the most proximate pathological substrate of cognitive impairment in AD compared

ix

with amyloid and tau deposition. Thus, a diagnostic tool is needed for detection of neuronal loss
in vivo. As a faster, non-invasive, and radiation free imaging technique, Magnetic Resonance
Imaging (MRI) plays an important role in the diagnosis of cognitive diseases. Conventional MRI
yields superb definition of brain anatomy and structure and provide important volumetric
information (e.g., brain atrophy). However, conventional MRI cannot provide microstructural
and functional insight into the pathology of AD.
The approach developed in Yablonskiy’s lab is based on the Gradient Echo Plural Contrast
Imaging (GEPCI) protocol, which provides quantitative in vivo measurements of transverse
relaxation properties of the tissue water 1H spins as determined from the gradient echo MRI
signal. The measurements are corrected for macroscopic magnetic field inhomogeneity effects
and physiologic-motion-driven fluctuations in magnetic field as these are the major artifacts
present with the gradient echo technique. The principal relaxation property used in this
dissertation is the tissue-specific transverse relaxation rate constant, R2*. The R2* value reflects
the microscopic and mesoscopic magnetic field inhomogeneities rising from the complex tissuewater-environment within the human brain. In turn, changes in R2* reflect changes in the
tissue’s microscopic and mesoscopic tissue structure.
However, because of the presence of the cerebral blood vessel network, the magneticsusceptibility-driven blood-oxygen-level dependent (BOLD) effect also makes a significant
contribution to R2*. A previously developed approach, quantitative BOLD (qBOLD), allows the
separation of R2* into a tissue specific R2t* without blood vessel effects and the BOLD
component. Quantifying the BOLD component allows the calculation of cerebral hemodynamics
parameters, such as oxygen extraction fraction (OEF) and deoxygenated cerebral blood volume

x

(dCBV). These parameters (R2*, R2t*, OEF, dCBV) describe structural and functional
properties of tissue at the microstructural level in the human brain.
In the study of normal aging, quantitative GEPCI measurements showed that R2t* increases with
age while hemodynamic parameters, i.e., relative OEF and dCBV remain constant in most
cerebral cortical regions. The comparison between quantitative GEPCI measurements and
literature information suggest that (a) age-related increases in the cortical R2t* mostly reflect the
age-related increases in the cellular packing density (or neuronal density); (b) regions in a brain
characterized by higher R2t* contain a higher concentration of neurons with less developed
cellular processes (dendrites, spines, etc.); and (c) brain regions characterized by lower R2t*
represent regions with lower concentration of neurons but more developed cellular processes.
In the Alzheimer study, R2* and R2t* together demonstrated significant differences among the
normal, preclinical and mild AD groups. First, the results uncovered strong correlations between
R2* and Aβ deposition measured by the PiB PET-tracer in several cortical regions (e.g., medial
temporal lobe and precuneus). This finding indicates that R2* may be a potential surrogate
marker for Aβ deposition. The strongest correlation was found in the medial temporal lobe
(MTL), particularly in the parahippocampal cortex, which can be used to distinguish the normal
and preclinical groups.
Second, R2t* in the hippocampus, which characterized the hippocampal cellular integrity
demonstrated much stronger correlations with psychometric tests than volume quantification of
hippocampal atrophy. Importantly, decreased R2t* characterizing cellular damage was detected
even in the hippocampal areas not affected by atrophy. In addition, R2t* significantly decreased
in the mild AD group but was preserved in the preclinical group compared with the normal
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group. These results indicate a significant cellular density decrease in the mild group but not in
the preclinical group, which is consistent with previous histological studies.
In summary, GEPCI provides a new approach for evaluation of AD-related tissue pathology in
vivo in the preclinical and early symptomatic stages of AD. Since MRI is widely available
worldwide and does not require radiation exposure, it provides the opportunity to obtain new
information on the pathogenesis of AD and for pre-screening cohorts (stratification) for clinical
drug trials.
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Chapter 1: Introduction to Gradient Echo
Plural Contrast Imaging (GEPCI)
1.1 MRI Basics
1.1.1 Nuclear Spins
In classic physics, a rotating object possesses a property known as angular momentum. The
angular momentum is related to the object’s size, mass, and rotational velocity. However, in
quantum mechanics, spin or spin angular momentum is an intrinsic property of atomic and
subatomic particles. The quantum spin number s is quantized, which means that it only takes
values of N/2, where N is a non-negative integer. So the spin angular momentum S of any
physical system is also quantized with the spin quantum number s and Planck’s constant h:

S

h
2

s( s  1) .

(1.1)

The component of S along any direction is calculated as follows:

Si 

h
si , si { s,  s  1,..., s  1, s} .
2

(1.2)

Thus, we see that S has 2s+1 components in different directions.
Due to the intrinsic spin, particles also have an intrinsic magnetic moment µ, which is the
product of the gyromagnetic ratio  and the spin angular momentum S:
 S .

1

(1.3)

The magnetic moment is used to describe how a small magnetic dipole (or current loop) interacts
with an external magnetic field. The magnetic energy of a particle (E) is the dot product of its
magnetic moment and the external magnetic field (B0):

E    B0 .

(1.4)

Let us take the proton as an example, because it is the most common source of MRI signal. The
quantum spin number s of a proton is ½. So there are 2  1  1  2 components of the spin angular
2

momentum S. Assume that B0 is applied along the Z direction and substitute µ with  and S. Then
the magnetic energy (E) of protons is written as follows:
E   S z B0  

h
 B0 .
4

(1.5)

We see that proton has two energy states in the presence of an external magnetic field (also
referred to spin-up and spin-down). The energy difference between the two states is written as
follows:

E 

h
 B0 .
2

(1.6)

According to Boltzmann statistics, the population ratio of the spins in the two states is calculated
as follows:

h B0
Population(anti  parallel )
E
 exp( )  exp(
),
Population( parallel )
kT
2 kT

(1.7)

where k is the Boltzman constant and T is the absolute temperature. At body temperature in a
field of 3.0 Tesla, the population ratio is nearly 1. Only a small excess on the order of 1 per 106
2

spins is expected to be found in the lower energy state. Fortunately, in a biological environment,
there is a large enough population of 1H to provide a sufficient MRI signal.

1.1.2 Free Induction Decay (FID) Signal
For convenience, in the field of magnetic resonance imaging, nuclear spins are usually
considered as the analogue of spins in classical physics. Thus, spins are considered to precess
around the magnetic field B0. The frequency of the precession is known as the Larmor frequency:

0   B0

.

(1.8)

We see that ΔE is proportional to the Larmor frequency as well, which is the frequency required
for the transition of the two energy states. Spins at equilibrium produce a net magnetization M0
along B0. It is convenient to use this net magnetization M0 to interact with B0 instead of
considering all the spins.
To understand the formation of the MRI signal, let us define a space with X, Y, and Z directions.
The external magnetic field, B0, is along the Z direction. In reality, the receiver coils are placed
on the transverse plane to detect the currents generated by the precession of the transverse
magnetization around B0. Thus, an electromagnetic radio frequency (RF) pulse with a nearly
Larmor frequency is usually applied perpendicular to B0 to flip M0 towards the XY plane by a
certain angle. At the quantum level, nuclear spins absorb the energy from the RF pulse with
Larmor frequency and are excited to the higher energy state. After the RF pulse is turned off, two
independent relaxations, T1 and T2* relaxations, occur simultaneously. A T1 relaxation is also
called a thermal relaxation, in which the spins release the absorbed energy to the surrounding
environment and return to the thermal equilibrium. As a result, the Z component (Mz) of the
magnetization grows back to M0 over time. For example, consider a 90 RF pulse that is applied
3

to flip M0 onto the transverse plane. After the RF pulse is turned off, Mz changes over time (t) in
accord with the following equation:

M z  M 0  (1  exp(t / T1 )) .

(1.9)

In the meantime, the nuclear spins start to dephase on the transverse plane due to magnetic-field
inhomogeneities—a process that is characterized as a T2* relaxation. The inhomogeneities
include irreversible and reversible parts. The irreversible part is caused by the fluctuating
magnetic fields generated from the spin-spin interactions—a process that is characterized as a T2
relaxation. There are three sources that induce a microscopic inhomogeneous field on the atomic
level: electron spin, electron orbital current, and nucleus spin. The reversible part is mainly due
to external fixed inhomogeneities, such as imperfect magnet and field distortion at the air/tissue
interface. The transverse magnetization (Mx,y) changes over time t, as in the following equation:

M x, y  M 0  exp(t / T2* )  cos(0  t  0 ) .

(1.10)

Due to T2* relaxation, the transverse magnetization Mx,y decays over time, which is referred to
as a free induction decay (FID) signal.

1.1.3 Gradients, Gradient Echo Sequence and K-Space
Although the FID can be measured, the signal comes from the whole object, and the signal at
each location on the object needs to be computed. Thus, a constant magnetic field gradient is
applied so that the overall magnetic field is linearly dependent on the location. For example,
consider a one-dimensional situation: The homogeneous magnetic field B0 is along the X
direction, and a gradient Gx is applied along the same direction. Then the distribution of the
overall magnetic field is linearly dependent on the location x:

4

B  B0  Gx  x .

(1.11)

Accordingly, the precession frequency is dependent on the location x:

   B  0    Gx  x

.

(1.12)

As a result, the location of a proton is encoded by its precession frequency, which is known as
frequency encoding. Frequency encoding provides a one-dimensional projection of spin density.
To get a two-dimensional image, we need to apply a gradient (Gy) in the orthogonal direction
(e.g., the Y direction) to the frequency-encoding gradient, which is known as the phase-encoding
gradient. The phase-encoding gradient is applied after the RF pulse and before the frequencyencoding gradient for a short period (on the order of millisecond). In this short duration, spins
accumulate a certain amount of phase to encode the location along Y direction. Likewise, a
three-dimensional image is created by adding an additional phase-encoding gradient along the Z
direction. The location along the Y and Z directions is encoded by the accumulated phase, while
the location along X is encoded by the precession frequencies.
Because all of the MRI experiments in my projects are based on the gradient echo (GE)
sequence, a diagram of the sequence to obtain a 2-D MRI image is shown below in Figure 1.1:

5

Figure 1.1 A diagram of the gradient echo sequence to obtain a 2-D MRI image.

First, a frequency-selective RF pulse is applied to flip the original magnetization M0 by a certain
angle (30 in GEPCI experiments). Concurrently, a slice-selective gradient is applied along the
slice direction (the Z direction) to excite spins in a targeting slice. However, the gradient brings
magnetic-field inhomogeneity and causes unwanted dephasing of the spins, which starts in the
middle of RF pulse duration. Thus, a rewinding gradient with exactly half the power of the slice
gradient follows to refocus the spins. Then a single step of the phase-encoding gradients is
applied over a certain duration to let the spins accumulate spatially dependent phase along the Y
direction. Next, a pre-rewind gradient is applied over exactly half of the read-out duration (t/2)
along the X direction. Then the readout gradient is turned on to refocus the spins and form an
echo at the gradient echo time (TE). In the meantime, the signal receiver is also turned on to
sample signals over time. The signal sampled during one read-out gradient is a single line of the
k-space. The same procedure is repeated at every time of repetition (TR) to fill in lines in kspace. Notice that, in every repetition, the phase-encoding gradients move to the next step (a new
6

gradient). When all of the repetitions are completed, the phase-encoding gradients move to the
last step and the k-space is fully filled. To obtain a 3-D image, replace the slice-selective gradient
with an additional phase-encoding gradient.
Assume that there is no other magnetic-field inhomogeneity except for the gradients along the
XYZ directions. The signal at each point during the read-out sampling can then be written as,
~

S (t )    ( x, y, z )  exp[i0 (TE  t )  i Gx xt  i Gy yt y  i Gz zt z ]  dxdydz ,

(1.13)

x, y , z

where  ( x, y, z) is the “ideal” signal at location (x, y, z) on the object. Notice the time is
represented as TE+t, where t is the time during GE acquisition (t is zero at the center of the GE).
To compute  ( x, y, z) , we substitute 2 k j   G j t j ( j  x, y, z ) , and the equation is rewritten as
follows:
~

S (k x , k y , k z )    ( x, y, z )  exp[i0 (TE  t )  2 k x x  2 k y y  2 k z z ]  dxdydz .

(1.14)

x, y , z

~

S (k x , k y , k z ) is the so called “k-space”. In GEPCI experiments, the k-space at each slice is
comprised of 256 lines, and each line is comprised of 256 points. Notice that k-space is the 3D
Fourier transform of the signal in the image domain  ( x, y, z) . So inverse Fourier transform is
applied to the k-space data to generate  ( x, y, z) :
~

 ( x, y, z )  FT 1[S (k x , k y , k z )] .

7

(1.15)

But in reality, the sampling during read-out duration is discrete. As a result, the signals in both
the k-space and the image domain are stored in voxels ( k x , k y , k z are integers). The signal within
a voxel is considered an integral over the locations. Thus, a fast Fourier transform (FFT)
algorithm is used in this case. Then the transformed image also stores signals in voxels. Different
notations would be used to distinguish the signal at a continuous point and a voxel.

1.2 Gradient Echo Plural Contrast Imaging (GEPCI)
The GEPCI technique is based on, (i) a 3D gradient echo (GE) sequence with multiple gradient
echoes (currently available from most MRI scanner manufacturers), and (ii) a set of postprocessing algorithms (1-6) that make it possible to generate images and quantitative maps with
several contrasts that reflect the anatomic and microstructural properties of biological tissue.
Importantly, all these GEPCI images are simultaneously acquired and are thus naturally coregistered.

1.2.1 MRI Data Acquisition
The scans were made in a 3T PET-MR scanner (Siemens, Erlangen, Germany). A 3D multi GE
sequence and a 12-channel phased-array head coil were used to obtain the data. The sequence
parameters were as follows: resolution 1×1×2 mm3 (read, phase, slab), FOV 256 mm×192 mm,
repetition time TR = 50ms, flip angle 30°, 10 gradient echoes with first gradient echo time TE1 =
4 ms, and echo spacing ∆TE = 4ms. An additional phase stabilization echo (the navigator data)
was collected for each line in k-space to correct for image artifacts due to the physiological
fluctuations (4). The total acquisition time of GEPCI was 11 mins 30s.
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1.2.2 Image Construction by Combining Multi-channel Data
Notice that MRI data is collected through a 12-channel RF coil. After the multi-channel data was
transformed from k-space to the image space by using inverse FFT, it was combined using the
following algorithm (2):
M

1
Sn (TE )   ch  S (TE1 )  S (TE ); ch 
M   ch2
ch 1
ch
n

ch
n

where the sum was taken over all M channels (ch),

M



ch1

2
ch

,

(1.16)

S n represents the signal at the nth voxel in

~

the image domain ( S is the signal in the k-space), S denotes complex conjugate of S ,
weighting parameters, and

ch are

 ch are noise amplitudes (r.m.s.) outside the human skull on the MRI

image. Index n corresponds to the voxel position. This algorithm allows for the optimal
estimation of quantitative parameters (2, 7) and removes the initial phase incoherence among the
channels (2).
Notice that we previously used  ( x, y, z) to denote the “ideal” signal at location (x, y, z) in the
image domain. Herein, we use

S n to represent the signal at a single voxel. It is not “ideal”

because of the effects of magnetic inhomogeneity.

1.2.3 Voxel Spread Function for Macroscopic Field Inhomogeneity Effects
Although gradient echo sequence is fast, the images can be adversely biased by macroscopic
magnetic-field inhomogeneities. So Sn (TE ) includes not only the “ideal” signal within the voxel,
but also the signal due to magnetic-field inhomogeneities. Yablonskiy’s lab reanalyzed a basic
theory of gradient echo MRI signal formation and developed a voxel spread function to model
the signal behavior in the presence of macroscopic magnetic-field inhomogeneities (3). For

9

example, Figure 1.2 shows that this function can significantly reduce artifacts on in vivo MRI
images due to the macroscopic magnetic-field inhomogeneity at the air/water interface.

Figure 1.2 Example of an R2* map corrected with and without the voxel spread function from a
healthy individual. Obviously, huge artifacts appear on the uncorrected R2* map on the left due
to the macroscopic magnetic-field inhomogeneity at the air/water interface (around nose). The
artifacts disappeared (right image) after the voxel spread function was applied.

The theory of this algorithm is briefly introduced here. Consider a 1-dimensional GE experiment.
In the presence of an inhomogeneous magnetic field b( x) , the MRI signal during the readout
period t is expressed in the following equation:
~

S (k x ; TE )    ( x; TE )  exp[2 ik x x  i b( x)(TE  t )  i0 ( x)]  dx ,

2 k x   Gxt x

(1.17)

where TE is the gradient echo time, x is the location in the image space, kx is a voxel in k-space,

Gx is the read-out gradients, t x is the duration of the gradient,
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 ( x; TE ) is the “ideal” signal at the

continuous location x in the absence of magnetic-field inhomogeneities, and 0 ( x) is the signal
phase shift at TE=0 (which results mainly from RF field inhomogeneities). Notice again that the
time is represented as TE+t, where t is the time during GE acquisition (t is zero at the center of
the GE).
The goal is to compute the “ideal” signal in a voxel, so we need to convert the continuous
equation to a discrete equation on the voxel level. Because the scale of macroscopic field
inhomogeneities is much larger than the size of a voxel, the distribution of b( x) and

0 ( x) in the

mth voxel is represented as a linear approximation:
bm ( x)  bm  g mx x

0 ( x)  0,m  mx x

where

mx

,

(1.18)

bm and 0,m are constants within the mth voxel but vary over voxels, and where g mx and

are the background gradients within the mth voxel. The “ideal” signal in the mth voxel

 m (TE )

is represented as a sum of  ( x; TE ) across the volume (V) of the voxel:.

 m (TE)  V    ( x; TE) m ,

(1.19)

where   ( x; TE ) m is the averaged signal in the mth voxel. So the signal is first integrated
across x in a single voxel and then the integral is substituted into Equation (1.17) with
summations of voxels:
~

S (k x ; TE )    m (TE )  exp(2 ik x x)  exp(i bm  TE  i0,m )  sinc[(k x  kmx )ax ]
m

2 kmx   g mxTE  mx
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. (1.20)

Inverse Fourier transform is applied to transform the k-space to an image domain. Thus, we have
the expression for the signal at the nth voxel in the image domain corrected for the macroscopic
magnetic-field inhomogeneity:
Sn (TE ) 

1
{ m (TE)  exp(i bmTE i0,m )  j sinc(kx, j ax  kmx ax )  exp[2 ikx, j ax (n  m)]} . (1.21)
N m

In general, the overall signal in the nth voxel is determined by all the voxels in the image
domain, including the “ideal” signal (  m (TE ) ), the accumulated phase due to the local
macroscopic magnetic inhomogeneity ( bm , 0,m ), and the interactions between a certain voxel
and other voxels (the sinc function part).
To make this algorithm computationally feasible, we have another approximation that the signals
from neighboring voxels evolve similarly over time in the absence of magnetic-field
inhomogeneities so that,

 m (TE )   n (TE )

Under this approximation, we can extract

| Sm (TE  0) |
.
| Sn (TE  0) |

(1.22)

 n (TE ) from the sum and reduce Equation (1.21) to,

Sn (TE )   n (TE )  Fn (TE )
Fn (TE ) 

.

1
  | Sm (0) |  exp( i bmTE  i0,m )   sinc( k x , j ax  kmx ax )  exp[2 ik x , j ax (n  m)]
| Sn (0) | m
j
(1.23)

where the F function

Fn (TE ) is the voxel spread function describing the influence of

macroscopic magnetic-field inhomogeneities at the nth voxel on the MRI image. The F-function
can also be extended to 2D or 3D versions. To finish the computation projects in a reasonable
12

time, we used only neighboring voxels of the target voxel to compute

Fn (TE ) instead of using all

the voxels.

1.2.4 Basic GEPCI Images (T1-weighted and R2*)
With the signals in the image space S (TE ) , the voxel spread function F (TE ) and a series of
TEs, the standard R2* = 1/T2* map, and a T1-weighted (A0) image and frequency (Δf) map will
be produced by fitting the following equation to experimental data on a voxel basis:
S (TE )  A0  exp   R2*  (TE  TE1 )  i  2  f  (TE  TE1   F (TE ) ,

(1.24)

where TE is the gradient echo time, Δf is the frequency shift (dependent on tissue structure and
also on the macroscopic magnetic field created mostly by tissue/air interfaces), and where the
function F(TE) describes the effects of macroscopic magnetic-field inhomogeneities (8). We use
a voxel spread function (VSF) method (3) to calculate F(TE).
Derived contrast images can also be constructed by using the same acquisition data according to
(6). But they are not used in the current projects.

1.3 Quantitative Blood-oxygen-level Dependent (BOLD)
Imaging
1.3.1 Blood-oxygen-level Dependent (BOLD) Effect
R2* is a good quantitative measurement for evaluating microstructural tissue properties.
However, except for the effect of the macroscopic magnetic-field inhomogeneity, there are more
complicated and subtle susceptibility effects in the tissue-water environment. Unlike the
macroscopic effect that biases the data, these susceptibility effects may provide interesting
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information about the tissue on the cellular level. One of the most important susceptibility effects
on the MRI signal is the blood-oxygen-level dependent (BOLD) effect discovered by Ogawa in
1990 (9). The paramagnetic deoxyhemoglobin in blood vessels causes additional FID signal
decay. Hemoglobin (Hb or Hgb) is a type of protein in red blood cells that contains iron and
transports oxygen. When it carries oxygen from respiratory organs, it becomes diamagnetic
oxyhemoglobin, the susceptibility of which is about -9 ppm, similar to that of water molecules in
the soft tissue. When it releases the oxygen to provide energy and collects the resultant carbon
dioxide back into the respiratory organs, it becomes paramagnetic deoxyhemoglobin with a
susceptibility of about 0.15 ppm. The difference of the magnetic susceptibility distorts the local
magnetic field and generates the BOLD contrast.
One of the most important applications of the BOLD effect focuses on temporal changes in the
MR signal during changes in brain activity, which is also known as function MRI (fMRI).
Furthermore, the quantitation of the BOLD signal can provide information about the
concentration of deoxyhemoglobin, which depends primarily on the oxygen extraction fraction
(OEF) and the deoxygenated cerebral-blood volume (dCBV). This allows the BOLD contrast to
be useful in understanding brain activities. However, the only clinically accepted OEF
measurement relies on PET techniques (10), which are limited in human study and clinical
practice due to their low spatial resolution and exposure to radiation.
A quantitative MRI-based approach has been developed to analytically describe the MRI signal
in the presence of a blood vessel network in the static dephasing regime (11). At first, this
approach was developed to evaluate the NMR signal in the presence of magnetic inclusions, such
as a blood vessel network, bone marrow, and a ferrite contrast agent. There are some common
behaviors for all the systems. If the echo time TE is less than a characteristic time tc for a given
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system, the signal decays exponentially with an argument which depends nonlinearly on TE.
When TE is greater than tc, the signal follows a simple exponential decay and the relaxation rate
does not depend on the echo time.
This approach was used to separate tissue-specific R2t* and BOLD-related contributions from
the total R2* relaxation (5, 12). The results for OEF, dCBV, and the concentration of
deoxyhemoglobin in the gray matter can also be robustly calculated using this approach. The
mean values of OEF and dCBV are 47% and 4.6%, respectively, which is in reasonable
agreement with the literature (5).
Several studies have been published to validate different aspects of this approach. Specifically,
we have developed a theoretical model of the BOLD effect (11), validated it in phantom studies
(8), conducted detailed measurements of blood magnetic susceptibility (13), validated the BOLD
model in vivo using a rat model (14), and provided an analysis of systematic errors due to
diffusion effects (15) and errors due to noise in the data (12, 16)

1.3.2 qBOLD Model for Magnetic Inclusions in the Static Dephasing Regime
Notice that this approach was developed on the assumption of a static dephasing regime in which
diffusion may be ignored (11). In general, the diffusion phenomena would average out the phases
of different nuclei. If NMR signal decay caused by magnetic moment dephasing occurs faster
than diffusion—which means that the signal would decay before the diffusion averages the
dephasing—then we are in the so-called static dephasing regime. If the water-diffusion
coefficient D=1 µm2/ms and the transverse size of blood vessel is ~10 µm, it takes 100 ms to
diffuse around a blood vessel. We can treat water molecules as static in the scan time (<40 ms).
That is a mesoscopic scale. On the microscopic scale, a transverse size of a molecule may be
~10A, so the water molecule would diffuse around and average the phase out before the signal is
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measured. Thus, the diffusion needs to be considered, and we can treat the medium (water
molecules, other small molecules) as a whole.

1.3.3 qBOLD Model for the Blood Vessel Network
Another major assumption is to model blood vessels as a set of cylinders with infinite length and
arbitrary radiuses that are randomly distributed in the medium. The signal behavior in the
presence of BOLD effect is then shown in

FBOLD (TE ) (11):

FBOLD (TE)  exp[  f s (  TE)] .

(1.25)

In practice, instead of the original function (11), we use a recently proposed expression (5),

FBOLD (TE )  1 


1
 f s (  TE ) 
 f s (    TE ) ,
1 
1 

(1.26)

that better accounts for the presence of large vessels in the voxel than traditional exponential
function (11).  is the deoxygenated cerebral-blood volume fraction (dCBV), and  is the
characteristic frequency determined by the susceptibility difference between deoxygenated blood
and surrounding tissue (11):

4
      B0  Hct  0  (1  Y ) .
3
In this equation,

(1.27)

x0  0.27 ppm (13) is the susceptibility difference between fully oxygenated

and fully deoxygenated blood, Y is the blood oxygenation level (with Y=0 being fully
deoxygenated), Hct is the blood hematocrit, and γ is the gyromagnetic ratio. Function

fs

describes the signal decay caused by the presence of the blood vessel network, which was
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defined in (11). Herein we use a mathematical expression in terms of a generalized
hypergeometric function 1 F2 (17):
  1 3 5 9

f s (  TE )  1 F2     ;  ,  ;  (  TE ) 2   1 .
  2   4 4  16


(1.28)

This function has an interesting behavior. The function is nonlinear when   TE  1 and linear
when   TE  1 , as is shown in Figure 1.3.

Figure 1.3 The non-linearity of function f s (  TE ) versus   TE when   TE  1 . The dots
are values at the time of echos (t = TEn) assuming Y = 60%.

Oxygen extraction fraction (OEF) is calculated as follows (18):
1

4

OEF  1  Y         B0  Hct   0  .
3


(1.29)

The concentration of deoxyhemoglobin per unit tissue volume is calculated as follows (18):
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3     nHb
Cdeoxy  
,
4      0  B0

where

nHb is the total intracellular Hb concentration equal to

(1.30)

5.5 106 mol / mL (18). Since Hct

was not measured in GEPCI experiments, we will report only relative regional OEF ( OEFrel )
values.

OEFrel   / mean

(1.31)

1.4 Summary
In summary, my dissertation primarily uses the following two models:
S (TE )  A0  exp   R 2*  (TE  TE1 )  i  2  f  (TE  TE1   F (TE )
S (TE )  A0  exp   R 2t *  (TE  TE1 )  i  2  f  (TE  TE1 )   FBOLD (TE )  F (TE )

,

(1.32)

where TE is the gradient echo time, R2t*=1/T2t* is the tissue transverse relaxation rate constant
(which describes GRE signal decay in the absence of the BOLD effect), Δf is the frequency shift
(which depends on tissue structure and on the macroscopic magnetic field, which is created
mostly by tissue/air interfaces), function

FBOLD (TE ) describes GRE signal decay due to the

presence of a blood vessel network with deoxygenated blood (veins and the part of capillaries
adjacent to veins), and function F(TE) describes the effects of macroscopic magnetic-field
inhomogeneities.
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By fitting the equation to the real and imaginary parts of the complex signal via a nonlinear
regression algorithm, we are able to find the six parameters A0, R2*, R2t*, Δf,  , and  for
each voxel in the brain. Based on the fitting results, we can calculate BOLD-related
measurements, including OEF, dCBV, Cdeoxy, and R2     . Examples of transverse MRI
images are shown below in Figure [4].

Figure 1.4 Example of transverse GEPCI images computed from the models.

The end of this chapter discusses these similar terms: R2*, R2, and R2t*. Note that,
conventionally, in a gradient echo experiment, the total R2* relaxation rate constant is
considered a sum of two components: the R2 relaxation rate constant, which represents the part
of MR signal decay that cannot be reversed by a refocusing 180° RF pulse; and the R2

19

relaxation rate constant, which represents the part of the signal decay that can be reversed by a
refocusing 180° RF pulse: R2*  R2  R2 . Because GEPCI is based on a gradient echo
sequence—although R2t* excludes the BOLD effect due to the blood vessel network—R2t* still
includes the reversible component due to the magnetic susceptibility effects that result from the
presence of different cellular components. This is the major difference between R2 and R2t*.
Furthermore, R2 is usually used to represent the spin-spin interactions in a single compartment
model where protons locate in a homogenous environment. However, due to the complicated
biological environment, protons may locate in multiple compartments: e.g., protons in myelin
layers, protons in axons, and protons in CSF. As a result, the interactions of protons with protons
and protons with other biological molecules are not homogenous in the multiple compartment
environment. In this circumstance, it is confusing to use R2 to represent all these spin-spin
interactions, so this is considered the irreversible part of R2t*. All in all, although R2t* excludes
the BOLD effect due to the blood vessel network, it still includes both an irreversible component
due to spin-spin interactions (e.g., protons with protons and protons with other molecules) and a
reversible component due to the susceptibility effects of biological components.
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Chapter 2: Introduction to Normal Aging
and Alzheimer’s Disease
Alzheimer’s disease (AD) affected approximately 48 million people worldwide in 2015. Its
devastating consequences have stimulated an intense search for AD prevention and treatment.
Although normal aging and Alzheimer’s disease can cause similar cognitive deficits and clinical
symptoms (e.g., memory loss), the underlying pathological changes are quite different. For
decades, it has been commonly believed that normal aging causes significant neuron death in the
neocortex and hippocampus. However, modern quantitative studies suggest that neuron number
is preserved in normal aging, so neuron death is unlikely to account for the age-related
impairment of neocortical and hippocampal functions. With significant brain atrophy and
neocortical thinning, one can hypothesize that the neuronal density increases with increasing age,
which is also supported by the literature. In contrast, there is considerable evidence for
significant neuron loss in the hippocampal area in Alzheimer’s disease. Previous studies have
also shown that neuronal damage is caused by neurotoxic pathological changes such as amyloid
plaques and tau tangles. Therefore, it is necessary to review the qualitative and quantitative
pathological changes of normal aging and Alzheimer’s disease with respect to neuron loss.
Currently, radiotracers and positron emission tomography (PET) imaging are widely used to
detect amyloid deposition and tau tangles in vivo. But there is also a potential for the GEPCI
approach to the in vivo detection of these microstructural changes that avoids the disadvantages
of PET imaging.
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2.1 Normal Aging
2.1.1 Non-significant Age-related Neuron Loss
Although it is well known that normal aging can cause functional cognitive impairments, the
neurobiological effects of normal aging (i.e., changes in the cellular content and organizations,
including cerebral cortical thinning and atrophy) on functional and structural declines are still not
well understood (19). A conventionally accepted idea dating back to the 1950s is that significant
neuron death is found both in aged humans without AD and in nonhuman primates and rodents
(20, 21). Although the percentage of neuron loss varies in these two studies, they both suggest
that most neocortical regions and certain hippocampal subfields lose neurons by 25% to 50%
with age. For example, Brody et al. (20) examined 20 brains of individuals between the ages of
newborn to 95 years. They report that the cell number decreased with age in all cortical layers.
The greatest decrease in cell number with increasing age occurred in the superior temporal gyrus
followed by the precentral gyrus and then the area striata. However, the data may be confounded
by species and strain differences, tissue processing, and sampling procedure.
Application of stereological procedures to count the neurons of several species, including
humans, yielded the surprising result that the number of neurons does not significantly change
due to normal aging in the cortex and hippocampus (19). Consider a few studies that support this
surprising result. Terry et al. (22) studied 51 brains from clinically and neuropathologically
normal individuals ranging in age from 24 to 100 years. They report that the total neuron
populations in the mid-frontal, superior temporal, and inferior parietal sections did not decline
significantly with age. Furthermore, the total neuron counts in the young group did not differ
significantly from those in the old group in the midfrontal cortex or the superior temporal cortex.
Only in the inferior parietal area is the difference significant, but the p value is 0.05 at the cut-off
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of significance level. Haug and Eggers (23) examined 60 brains and report that the brain volume
of frontal cortex significantly decreased but that loss of neurons cannot be found. As a result, the
neuronal density increased in the frontal cortex. Furthermore, the size of neurons and the number
of synapses decrease with age. Pakkenberg and Gundersen (24) examined 94 brains from a
Danish population and report that the average numbers of neocortical neurons are 19 billion in
female brains and 23 billion in male brains: a 16% gender difference. A rather small decline
(approximately 10%) of neocortical neurons were found over the life span from 20 to 90 years in
the human neocortex. However, they warn that, due to the experimental design, this small
decline with age should not be considered strong evidence for biologically significant age-related
neuron loss. Pakkenberg et al. examined the same 94 brain samples in 2003 (25) and report that
the number of glial cells in six elderly individuals with a mean age of 89.2 years was not
significantly different from that of six young individuals with a mean age of 26.2 years.
Furthermore, the total myelinated fiber length varies from 150,000 to 180,000 km in young
individuals and shows a large reduction with age. Freeman et al. (26) examined the cerebral
cortex of 27 normal individuals ranging in age from 56 to 103 years. They found that the frontal
and temporal neocortical regions exhibited clear evidence of cortical thinning with age but that
total neuronal numbers in the frontal and temporal neocortical regions remained relatively
constant over a 50-year age range. As a result, frontal and temporal cortical neuronal density
showed a small but insignificant increase with increasing age. Freeman et al. also discuss what
leads to cortical thinning. The data suggest that loss of neuronal and dendritic architecture, rather
than loss of neurons, underlies neocortical volume loss and cortical thinning with increasing age
in the absence of AD.
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Based on the findings in literature, we can see neuron loss is not significant due to normal aging.
In addition to neurons, the number of other CNS cells such as glial cells did not show significant
differences between elderly individuals with a mean age of 89 years and young individuals with
a mean age of 26 years (25). Furthermore, the glia/neuron ratio of 1.32 for females and 1.49 for
males showed no statistically significant correlation with age over adult life (27). Thus, the
published studies indicate that the total number of neurons and glial cells in the cortex remains
relatively constant over normal adult life.

2.1.2 Age-related Brain Atrophy and Cortical Thinning
Cerebral volume loss and cortical thinning has been observed in various structural MRI studies
associated with normal aging. A few studies are cited to support this observation. Scahill et al.
(28) scanned 39 healthy control subjects ranging in age from 31 to 84 years. They find a
significant decrease in cross-sectional whole brain, temporal lobe, and hippocampal volumes,
and a significant increase in ventricular volume with age. Fotenos et al (29) also used structural
MRI to scan 370 adults ranging in age of 18 to 97 years. 192 participants were non-demented,
while the rest (98 participants) exhibited very mild to mild dementia of the Alzheimer type. They
find that both cortical and white-matter volume decrease with age; gray matter volume declines
in a linear fashion from early adulthood, whereas white matter volume loss appears to start later
in life and does not follow a linear pattern. The onset of dementia is associated with an
accelerated atrophy rate.
Thinning of the cerebral cortex over age has also be found in many studies. A few studies are
cited here to support this statement. Salat et al. (30) measured the cortical thickness in 106 nondemented participants ranging in age from 18 to 93 years by using a T1-weighted MRI. They
find that the global thickness significantly declines with increasing age. In regional measures,
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significant thinning was found in the occipital lobe, the pre/post central gyrus, and the inferior
lateral prefrontal cortex. Temporal lobe thinning is relatively less significant compared to that
observed in other cortical areas. Similarly, our study (Chapter 3) (12) also shows that cortical
thickness significantly decreases with age in most of the cortical regions segmented in
FreeSurfer. The thinning rate varies across cortical regions of the brain. The 20 participants in
this study were healthy controls ranging in age from 22 to 74 years.

2.1.3 Neuronal Density may Increase with Age
The unchanged number of neurons and the decreasing cortical volume imply increasing neuronal
density with increasing age in the cortex, which is also supported by the results of Haug and
Eggers (23, 31). They performed morphometric analysis of neurons on human brains and
measured five Brodmann cortical areas. These areas include, (i) area 6 in the frontal lobe, also
designated the supplementary motor area; (ii) area 11 in the orbital part of the frontal lobe, which
is linked to psychosocial functions; (iii) area 7 in the parietal lobe, which is related to sensory
and speech analysis; (iv) area 17 or the visual cortex in the occipital lobe; and (v) area 20 at the
basis of the temporal lobe. The measurements are based on at least 50 brains in each area, except
for area 20, for which the measurements of only 20 brains are provided. They find that the
neuron density increases significantly with age in areas 6 and 11 in the frontal lobe (p = 0.01)
and in area 17 in the occipital lobe (p = 0.001), while area 7 in the parietal lobe and area 20 in the
inferior temporal gyrus show non-significant but increasing tendencies. They also confirm that
the total number of neurons in the human cerebral cortex does not change during normal aging.
This result may not be representative of brain regions other than the cortex.
As mentioned above, Freeman et al (26) also find that frontal and temporal cortical neuronal
density shows a small increase with increasing age. Although few studies directly measure
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neuronal density over age, the unchanged number of neurons and cortical thinning with age are
widely supported by previous studies, which is a strong indications of increased neuronal
density.

2.1.4 Age-related Dendritic and Synaptic Loss
But if loss of neurons is not significant in normal aging, what leads to cortical thinning and
volume loss? A more recent point of view is that relatively subtle alterations in synaptic
connectivity, dendritic spine density, and neural plasticity (32-35) are associated with age–
related cognitive dysfunctions. A significant reduction in the dendritic arbors of pyramidal
neurons located in the prefrontal, superior temporal, and precentral cortices, and changes in
dendritic spine size, shape, and density across the neocortex in humans and animals are discussed
by Dickstein (33). Hof and Morrison (34) argue that, while neuron death predominates in
Alzheimer’s disease, age-related cognitive impairment is probably mediated by changes in
synaptic communication rather than by neuron death. Fjell et al. (32) also argue that regions
with a high degree of life-long plasticity are more affected by normal aging effects. Freeman et
al. (26) argue that previous studies suggest an age-related decrease in neuronal size (13) and a
loss of presynaptic terminals (28). A loss of complexity of dendritic arborizations has also been
described in Golgi studies of “normal” aging. The reported observation of volume loss in the
white matter also suggests that some of the decrease in cortical thickness could be attributed to
loss of ascending projections in the cortex. Together, these data suggest that loss of neuropil (i.e.,
neuronal structural complexity) might contribute to the dramatic thinning that occurs with
increasing age.
In summary, much evidence shows that neuron loss is not significant over the normal aging
process, while cerebral atrophy and thinning are significant. Thus, neuronal density should
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significantly increase with age. However, most of the studies cited that are related to neuronal
structure were conducted on non-human primates or other animals or on post-mortem human
tissues. Hence, it is essential to study the age-related cellular and functional alterations
quantitatively in vivo and to establish a baseline for distinguishing normal aging from
pathological effects.

2.2 Alzheimer’s Disease
2.2.1 A Staging Model of Alzheimer’s Disease
Over the past two to three decades, a staging model of Alzheimer’s disease (AD) has been
developed. Both AD pathological processes and clinical decline progress gradually. Pathological
changes begin to develop decades before the earliest clinical symptoms occur. Dementia occurs
at the last stage of many years of accumulation of these pathological changes. At present, the
clinical diagnosis of AD requires the presence of dementia.
The clinical disease stages of AD have been divided into three stages (36). The first is referred to
as a pre-clinical stage in which individuals are cognitively normal but have AD pathological
changes. Notice that some of these individuals die without ever showing AD clinical symptoms.
The hypothesis is that an asymptomatic individual with AD-related pathological changes would
ultimately have become symptomatic if he or she lived long enough. The second is commonly
referred to as mild cognitive impairment (MCI), in which the earliest cognitive symptoms
(typically deficits in episodic memory) occur but do not meet the criteria for dementia. The
severity of cognitive impairment in the MCI stage varies from the earliest appearance of memory
loss to more widespread dysfunction in other cognitive domains. The final phase in the evolution
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of AD is dementia, in which impairments in multiple domains are severe enough to produce
cognitive deficits.
Dementia is the clinically observable result of the cumulative burden of AD pathological
changes in the brain. A clinical diagnosis of dementia indicates that the patient has a disorder
that precludes independent living and is on an inevitable course toward complete loss of
independence. Most elderly patients with dementia have multiple pathological changes
underlying their dementia. AD is the most common pathological substrate, which is referred to as
dementia of the Alzheimer type (DAT).
To date, all disease-modifying experimental therapies for AD have failed to demonstrate a
clinical benefit in individuals with symptomatic AD (37, 38), possibly because the drugs were
administered too late in the course of the disease, which begins 15-20 years prior to the onset of
clinical symptoms (36, 39-45). As a result, the preclinical stage is an important time window for
therapeutic intervention. Hence, one of the important directions in AD therapy is to develop
widely accessible neuroimaging techniques that can detect AD brain pathology in the preclinical
stages. Many biomarkers have been developed to detect pathological changes in the preclinical
stage and to identify individuals who are destined to develop AD in the early disease course.
Herein, several hallmark AD pathological changes and widely used biomarkers are introduced
briefly.

2.2.2 Amyloid Deposition
One of the prevailing hypotheses of AD is the amyloid cascade hypothesis (36, 39, 41, 42),
which suggests that abnormal accumulation of (Aβ) in the neocortex is one of the earliest
pathological markers of AD. Aβ deposition is actually the product of a larger transmembrane
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protein: the amyloid precursor protein (APP) (46). The abnormal metabolism of APP leads to
excess production or reduced clearance of Aβ in the cortex.
Both CSF Aβ42 and radiotracers of amyloid PET imaging are biomarkers of Aβ deposition. Klunk
et al. (47) report the first human study of a novel amyloid PET imaging tracer—Pittsburgh
Compound-B (PiB)—in 16 patients with diagnosed mild AD and 9 controls. The retention of PiB
measured by PET imaging (PiB PET) in vivo reveals a large amount of amyloid deposits in
cerebral cortical areas of the AD brains, especially in the prefrontal cortex and precuneus (47,
48). PiB retention was equivalent in both AD patients and controls in areas known to be
relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and
cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 ± 11 years)
showed low PiB retention in cortical areas and no significant group differences between young
and older controls. Later on, Ikonomovic et al. (49) examined patients who underwent PiB PET
imaging before death and autopsy. They report a strong direct correlation between PiB retentions
in vivo and region-matched quantitative measures of amyloid plaques of the AD subjects. They
also find that PiB binds specifically to fibrillary Aβ and not to soluble Aβ or diffuse Aβ plaques.
This study further supports the validity of PiB-PET imaging as a method for in vivo evaluation of
Aβ plaque burden.
Low concentrations of CSF Aβ42 correlate with both the clinical diagnosis of AD and with Aβ
neuropathology at autopsy. An inverse relation has been reported between in vivo PiB amyloid
imaging and CSF Aβ42 in AD patients who have undergone both tests (50). The evidence
therefore strongly supports the hypothesis that both amyloid imaging and low CSF Aβ42 are valid
biomarkers of brain Aβ-plaque load.
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However, amyloid deposition has been shown to start while individuals are still cognitively
normal. It is hypothesized that, after an early phase of fast accumulation, a plateau is reached by
the time of cognitive decline (36). In the study by Villain et al. (51), 32 patients with AD, 49
subjects with MCI, and 103 healthy controls underwent two PiB PET scans 18 months apart.
They report no significant association between the PiB retention rate of change and the clinical
status or disease progression. Amyloid accumulation seems to slow down at the latest stages of
the process.

2.2.3 Neurofibrillary Tau Tangles
So amyloid deposition is not related to clinical symptoms as closely as another hallmark
abnormal protein deposit: neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau.
Bennett et al. (52) examined 44 individuals with clinically diagnosed AD and 53 without
dementia with a uniform structured clinical evaluation for AD and cognitive testing about 8
months prior to death, and brain autopsy at death. They report that, when a term for tau tangles is
added to the multiple regression model with amyloid, the association of amyloid load with
clinical disease or global cognitive tests is reduced by more than 60% and is no longer
significant, whereas the association of tangles with clinical disease is essentially unchanged.
Giannakopoulos et al. (53) examined 22 elderly cases with clinical dementia assessment
(MMSE), stereological assessment of NFT, unaffected neurons, and total amyloid volume in the
CA1 field of the hippocampus, entorhinal cortex, and Brodmann area 9 (frontal area).
Multivariate analyses show that total NFT counts in the entorhinal cortex and area 9 as well as
neuron numbers in the CA1 field are the best predictors of the MMSE score. The amyloid
volume has no additional predictive value, in terms of clinicopathologic correlations, beyond its
interaction with NFT.
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However, the prior lack of imaging agents has limited studies of tau to postmortem examinations
or measures that lack topographic information such as measurement of tau in CSF. A recent
study by Brier et al. (54) reports PET imaging of tau and Aβ in a cohort of cognitively normal
older adults and older adults with mild AD. They also discuss the fact that tau deposition in the
temporal lobe more closely tracks dementia status and is a better predictor of cognitive
performance than Aβ deposition in any region of the brain.

2.2.4 Neuron Loss in the Hippocampal Area
However, an autopsy study has confirmed that gross cerebral atrophy (indicating the loss of
synapses and neurons), and not Aβ or NFT burden, is the most proximate pathological substrate
of cognitive impairment in AD. For example, Savva et al. (55) assessed 456 brains from people
69 to 103 years of age at death. They report that the associations between dementia and
pathological changes (amyloid deposition and tau tangles) attenuate with increasing age. In
contrast, atrophy of the hippocampus and the neocortex is strongly associated with dementia at
all ages.
Based on the above discussions, Aβ abnormalities precede tau abnormalities and NFTs precede
cerebral atrophy. Additionally, patterns of gray matter loss are associated with NFT pathology at
Braak stages V and VI (56). 83 subjects with Braak stage III through VI underwent ante-mortem
and post-mortem AD staging. The Braak stage V and VI groups showed a pattern of gray-matter
loss affecting the medial temporal lobes (MTL), including the hippocampus, the entorhinal
cortex, and the adjacent parahippocampal gyrus, which is vulnerable to NFTs. Subjects with a
high tau burden showed a pattern of gray-matter loss affecting the hippocampus,
parahippocampal gyrus, and lateral temporal lobes compared with subjects with a low tau
burden.
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Indeed, the medial temporal lobe is an essential area related to human memory and to AD.
Reduction of volume and loss of cells in the entorhinal cortex and hippocampus have been
extensively reported in participants with mild cognitive impairment (MCI) and AD (57-61). For
example, Price et al. (59) examined the neuron number and volume in the entorhinal cortex and
CA1 field of the hippocampus from 4 groups of participants, including 13 non-demented cases
with healthy brains, 4 cases with preclinical AD, 8 cases with very mild symptomatic AD, and 4
cases with severe AD. They report no significant decrease in neuron number or volume with age
in the healthy non-demented group and little or none in the healthy and preclinical AD groups.
They report substantial decreases in neuron number and volume in the very mild AD group.
Greater damage was observed in CA1 in the severe AD group. The results indicate that
symptomatic AD begins only when neuron loss occurs in the hippocampal area, which is
consistent with the study by West et al (62).
The posterior parahippocampal gyrus draws relatively less attention, but several studies have
reported its atrophy due to aging (63) and AD (64). The presence of neurofibrillary tangles
(NFTs) and neuronal loss in the parahippocampal gyrus—previously reported by Thangavel et al
(65)—can also affect R2* measurements. However, their participants were assessed at death
after nearly a decade of dementia. In addition, tissue damage in the parahippocampal gyrus was
smaller than that in the hippocampus (66).

2.2.5 Clinical Dementia Rating (CDR)
The above sections introduce hallmark AD pathological features. This section introduces a
clinical evaluation for identifying cognitive impairment. This evaluation, referred to as clinical
dementia rating (CDR), has been developed by Washington University. The CDR is a 5-point
scale used to characterize six domains of cognitive and functional performance applicable to
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Alzheimer disease and related dementias: memory, orientation, judgement & problem solving,
community affairs, home & hobbies, and personal care. The necessary information to make each
rating is obtained through a semi-structured interview of the patient and a reliable informant or
collateral source (e.g., a family member). The score is useful for characterizing and tracking a
patient’s level of impairment/dementia:
0 = Normal
0.5 = Very Mild Dementia
1 = Mild Dementia
2 = Moderate Dementia
3 = Severe Dementia
The scoring rule is to use all of the information available and to make the best judgement. Score
each category (M, O, JPS, CA, HH, PC) as independently as possible. Mark in only one box for
each category, rating impairment as a decline from the person’s usual level due to cognitive loss
alone, not impairment due to other factors, such as physical handicap or depression. Occasionally
the evidence is ambiguous and the clinician’s best judgment is that a category could be rated in
either one of two adjacent boxes, such as mild (CDR=1) or moderate (CDR=2) impairment. In
this situation, the standard procedure is to check the box of greater impairment. The derivation of
the global CDR from the scores in each of the six categories is described in detail by Morris (67).

2.3

MRI Application in Microstructural Changes
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As mentioned above, PET imaging is widely used to measure the retentions of biomarkers of
amyloid and tau deposition in AD studies. But MRI is widely available worldwide, is noninvasive ,and does not require radiation exposure. For both normal aging and AD, a structural
MRI can provide accurate volume measurements as post-mortem measurements. For example,
Bobinski et al. (68) examined 11 AD cases and 4 healthy controls and measured the post-mortem
volumes of the hippocampal subdivisions by using MRI and histological sections. They report
strong correlations between these two measurements, which indicate that an accurate volumetric
measurement of the hippocampus can be obtained via MRI. However, atrophy occurs at a later
stage of the AD process, so structural MRI cannot effectively give an early diagnosis for the
preclinical stage. Furthermore, the volumetric measurements lack biological information, so a
quantitative MRI technique is needed to identify early AD pathological changes and to provide
biological information at a microstructural level.
This is possible because all of the AD pathological processes that contribute to the pathogenesis
of Alzheimer’s disease at the cellular level lead to changes in the environment of local tissue
water molecules – a major source of MRI signal. Hence, in addition to measuring brain atrophy
by using volumetric MRI, a properly designed MRI technique can enable local water molecules
to report on regional biological tissue properties at the cellular level.
The GEPCI approach could be a potential candidate for this motivation. The GEPCI approach
has been used to identify brain tissue damage in multiple sclerosis (2, 4, 69-72) and psychiatric
diseases (73). R2* values have been found to be significantly lower in patients with multiple
sclerosis (MS) than in healthy participants (2, 4, 69-72). Significant correlations between ageadjusted R2* measurements and clinical scores of MS have also been reported for cortical
regions (71). Significant group effects based on GEPCI measurements have been observed in the
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superior temporal cortex and in the thalamus in participants with schizophrenia and bipolar
disorder Because GEPCI metrics (R2* and R2t*) are sensitive to the tissue-water environment in
the human brain, the measurements can be very hard to interpret. As a result, GEPCI is first
applied to study healthy controls with normal aging, (i) to establish an age-related baseline, and
(ii) to gain a better understanding of the biological interpretation of GEPCI metrics (12). GEPCI
is then utilized to detect the pathological changes of the preclinical and the early Alzheimer
disease in vivo (74).
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Chapter 3: On the Relationship between
Cellular and Hemodynamic Properties of the
Human Brain Cortex Throughout Adult
Lifespan
3.1 Introduction
Establishing baseline MRI biomarkers for normal brain aging is significant and valuable for
separating normal aging effects from neurological diseases. In this study, for the first time we
have simultaneously measured a variety of tissue specific GEPCI metrics of healthy adults (ages
22 to 74 years), such as T1-wegihted, R2*, R2t*, OEF, dCBV and Cdeoxy. GEPCI metrics are
utilized to establish quantitative in vivo biomarkers characterizing the age-related evolution of
tissue structural and functional properties of adults. Two main goals of this study are: (i) to
investigate the age-related changes of GEPCI metrics so a baseline for normal aging can be
established; (ii) based on GEPCI age-related results and what we know about the pathology of
normal aging from the literature (reviewed in Chapter 2), find out a proper biological
interpretation for GEPCI metrics, especially R2* and R2t*. Both the age-related baseline and the
biological interpretation of GEPCI metrics are essential for us to investigate diseases in the
future.
The data (20 healthy subjects) show that in most cortical regions R2t* increases with age while
tissue hemodynamic parameters, i.e., relative oxygen extraction fraction (OEFrel), deoxygenated
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cerebral blood volume (dCBV) and tissue concentration of deoxyhemoglobin (Cdeoxy) remain
practically constant. R2t* describes the part of the signal decay resulting from water molecule
interactions with cellular and extracellular components of biological tissues. By comparing our
results with the literature data, we hypothesize that in the normal brain it can serve as a
biomarker of the cortical “cellular packing density” – a parameter mostly proportional to the
number of neurons and glia cells in the unit tissue volume – and can potentially identify tissue
alterations (see further comments in the Discussion section). We also use this hypothesis to
explain the relationships between R2t* and the functional data (e.g., OEF). Specifically, thicker
cortical regions have lower R2t* and these regions have lower OEF.
The baseline GEPCI-based biomarkers obtained herein could also serve to help distinguish agerelated changes in brain cellular and hemodynamic properties from changes which occur due to
neurodegenerative diseases, e.g., (71).

3.2 Methods
3.2.1 Participants
This study was approved by the Institutional Review Board of Washington University School of
Medicine. Twenty participants aging from 22 to 74, including 7 male (ages: 22, 26, 29, 35, 37,
42, 65) and 13 female (ages: 23, 28, 33, 42, 45, 46, 50, 52, 56, 57, 61, 61, 74), were recruited in
this study. None of the participants had any history of neurological diseases. All participants
provided informed consent.
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3.2.2 Data Acquisition
All subjects were scanned in a 3T Trio MRI scanner (Siemens, Erlangen, Germany). A 3D multi
gradient echo sequence was used to obtain the data. Sequence parameters were: resolution 1×1×2
mm3 (read, phase, slab), FOV 256 mm×192 mm, repetition time TR = 50ms, flip angle 30°, 10
gradient echoes with first gradient echo time TE1 = 4 ms, echo spacing ∆TE = 4ms. Additional
phase stabilization echo (the navigator data) was collected for each line in k-space to correct for
image artifacts due to the physiological fluctuations (4). The total acquisition time of GEPCI is
11 mins 30s. Field inhomogeneity effects were removed by using the voxel spread function
(VSF) approach (3). Standard clinical Magnetization-Prepared Rapid Gradient Echo (MPRAGE)
(75) images with TR/TI/TE = 2200/1100/3.37 ms and the resolution 0.9×0.9×1.5 mm 3 were also
collected for segmentation purposes. The total acquisition time of MPRAGE is 6 mins. After the
data acquisition, the raw k-space data were read into MATLAB (The MathWorks, Inc.) for the
post-processing.

3.2.3 Data Analysis and Image Generation
The image processing was finished in MATLAB (The MathWorks, Inc.) using models described
in Chapter 1:
S (TE )  A0  exp   R 2*  (TE  TE1 )  i  2  f  (TE  TE1   F (TE )
S (TE )  A0  exp   R 2t *  (TE  TE1 )  i  2  f  (TE  TE1 )   FBOLD (TE )  F (TE )

(3.1)

where TE is the gradient echo time, R2* is the global transverse relaxation rate constant,
R2t*=1/T2t* is the tissue transverse relaxation rate constant in the absence of BOLD effect, Δf
is the frequency shift (dependent on tissue structure and also macroscopic magnetic field created
mostly by tissue/air interfaces), function

FBOLD (TE ) describes GRE signal decay due to the

presence of blood vessel network with deoxygenated blood (veins and the part of capillaries
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adjacent to veins), and function F(TE) describes the effects of macroscopic magnetic field
inhomogeneities.
As mentioned in Chapter 1, by fitting the equation to the real and imaginary parts of the complex
signal using nonlinear regression algorithm, six parameters are computed: A0 (T1-weighted),
R2*, R2t*, Δf,  and  for each voxel in the brain.  and  are computed from

FBOLD (TE ) .

Based on the fitting results, BOLD-related measurements are computed, including OEF, dCBV,
and Cdeoxy.
In this study, the relative regional OEF (OEFrel) is reported as:

OEFrel   / mean

(3.2)

where mean is the mean across the cerebral cortex and  represents one single cortical region.

3.2.4 Image Segmentation
MPRAGE images were input into FreeSurfer (Laboratory for Computational Neuroimaging,
Martinos Center for Biomedical Imaging) (76) to generate brain segmentations and calculate
cortical thickness. 26 cortical regions of interest (ROI), covering frontal, temporal, parietal and
occipital lobes, were chosen to characterize an individual participant’s cortex. The thalamus,
caudate, putamen, pallidum, hippocampus and amygdala were chosen to study the subcortical
regions.
MPRAGE images were registered to GEPCI-T1-weighted images using FMRIB’s (Functional
Magnetic Resonance Imaging of the Brain) Linear Image Registration Tool (77, 78) in FMRIB
Software Library (FSL) and the transformation matrices of the registration were computed.
Finally, these matrices were applied to the brain segmentations from FreeSurfer and transformed
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them to the space of GEPCI-T1-weighted images. Since GEPCI –T1-weighted images are
naturally co-registered with all GEPCI maps (R2*,R2t*, OEFrel, Cdeoxy, and dCBV), the
segmentations were also naturally registered to all these maps.
Even though the data were collected with rather high in-plane resolution – 1x1 mm2, they are
still susceptible to the partial volume effect (edge values, outliers). To minimize it, a CSF mask
generated from FSL is applied further removing CSF signals from FreeSurfer segmentations.
Furthermore, in each of the FreeSurfer ROIs which usually contains thousands of voxels, the
median of the corresponding measurement distribution was computed because it is less sensitive
to outliers. This procedure also minimizes the errors in the model parameters estimates discussed
in 3.2.6 Error analysis.

3.2.5 Image Segmentation
The correlations and linear regressions were established using the LinearModel class in
MATLAB (The MathWorks, Inc.). As mentioned above, for each GEPCI parameter, the median
value was calculated across thousands of voxels within each Freesurfer ROI. As a result, an
individual participant has 7 parameters (R2*, R2t*, OEFrel, dCBV, Cdeoxy, cortical thickness (Th),
and SR2t*=R2t*×Th) and 26 median values from the cortical ROIs for each parameter. So for
each parameter and each ROI, the following equation is used to calculate a correlation and linear
regression between the parameter and age across 20 participants:

parameterROI  aROI  kROI  (age  40)

(3.3)

Age 40 years was selected arbitrarily as the adult reference age for the convenient interpretation
of the intercept

aROI . Then aROI represents the characteristic value of a parameter within a ROI
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taking into account all 20 participants.
are 26

aROI corresponds to an averaged 40-year old adult. There

aROI and kROI for each parameter across the cortical ROIs. To visualize the distribution of

the parameters across 26 cortical ROIs,

aROI can be mapped onto the Freesurfer brain surface.

aROI is used to investigate the relationship between parameters across 26 cortical ROIs. If the
parameter doesn’t have a significant linear relationship with age, the characteristic value of the
parameter within a ROI is just the average across all the participants. The p-values were
calculated to evaluate each correlation and conventionally p < 0.05 is considered as a significant
correlation. Multiple comparison analysis was not applied here because we only reported
individual correlations instead of comparing them across different ROIs.

3.2.6 Error Analysis
The simulated data were generated to test the accuracy of the theoretical model, Equation (3.1),
used in this study. As the frequency ( f ) has minimal effects on the fitting process, only the
amplitude of the signals were used in this simulation. First, the true values of the parameters
were assigned based on our typical results: R2t* = 17, OEF = 40%, and dCBV = 3%. Then the
parameters were substituted into Equation (3.1) to generate the “true” signals over 10 TEs from
4ms to 40ms. Second, a set of “real” signals over 10 TEs was generated by adding the random
noise to the true signals. A typical SNR in GEPCI experiments is between 300 and 500 (for
Hanning filtered data). In the simulated data, the noise corresponding to SNR equal to 400 is
used. The random noise values were drawn from the standard normal distribution generated by a
built-in function in MATLAB. In total, 500,000 sets of the simulated signals were generated in
this way. Third, the same fitting routine was applied to each set of the simulated signals to
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calculate the output parameters. Finally, the medians, means and standard deviations of each
parameter were calculated.

3.3 Results
3.3.1 Age-related Changes in the Cerebral Cortex

42

Figure 3.1 Examples of the scatter plots of (a) R2*, (b) R2t*, (c) OEFrel (local-to-global ratios,
Eq. [2]), (d) dCBV, (e) Cdeoxy, (f) cortical thickness (Th) and (g) SR2t* versus age are shown in 4
selected cortical ROIs. Each plot represents the data from a single cortical region and each point
in the plot represents a single participant. Male subjects are represented by blue points and
female subjects by red points. For R2*, R2t* and cortical thickness, the solid lines are the
regression curves and the p values evaluate the significance of the linear model. SR2t*, OEFrel,
dCBV and Cdeoxy show no significant change with age and are represented by a constant model
(the solid lines). The dashed lines in all plots represent the 95% confidence intervals. Number of
asterisks or “stars” show significance level: p < 0.01 (**), p < 0.05 (*). The results of regression
analysis from all other regions are listed in Table 3.1 and Table 3.2.

The data (Figures 3.1 and 3.2, Tables 3.1 and 3.2) show that in most cortical regions R2* and
R2t* increase with age, OEFrel, dCBV and Cdeoxy remain constant while cortical thickness, Th,
decreases. In addition to parameters listed above, we have also introduced a parameter SR2t*
that represents an integrated characteristic of R2t* under a unit square of the cortex and is
computed as a product of the median R2t* and Th for each FreeSurfer region: SR2t*=R2t*×Th.
The detailed role of this parameter will be addressed in the Discussion section.
Figure 3.1a shows that R2* statistically significantly increased (p < 0.05) with age in the
example cortical ROIs. Furthermore, 21 out of 26 regions listed in Table 3.1 demonstrated that
R2* significant increase over age with varying rates (slopes). Although a few regions showed
non-significant results, all slopes were positive demonstrating an increasing trend of R2* over
age.
Figure 3.1b shows that R2t* also significantly increased (p < 0.05) with age in the example
ROIs. Furthermore, 15 out of 26 regions listed in Table 1 showed significant increase over age
with varying rates (slopes). In general, p values for R2t* regression are higher than those for R2*
regressions. As a result, a few regions with significant increases in R2* showed non-significant
increases in R2t*. For example, in the insula cortex, R2* significantly increased with age (p =
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0.020) while R2t* did not (p = 0.14). Again, all slopes were positive. So although some regions
didn’t have significant results, there was always an increasing trend of R2t* over age.
Figure 3.1c shows that the relative OEF (OEFrel, a local-to-global ratio, Equation (3.2)), showed
no significant trend with age – the p values of the linear model were not significant (p > 0.05) in
all cortical regions except the rostral-middle frontal (p= 0.013) and the lateral occipital (p=
0.026). To describe this data, a constant model is used in all cortical regions. The mean values of
OEFrel are shown in Figure 3.1 as solid lines with the 95% confidence intervals shown as dashed
lines. The mean values and standard deviation were listed in Table 3.2. The mean values of
OEFrel ranged from 0.6 to 1.5 across the selected 26 ROIs. The regions in occipital lobe, such as
cuneus, lingual and lateral occipital, have comparatively higher OEFrel (Table 3.2).
Results for dCBV (Figure 3.1d and Table 3.2) and Cdeoxy (Figure 3.1e and Table 3.2) showed
similar properties as OEFrel. They have no statistically significant linear trend over age. As a
result, a constant model was used for them. The mean values and standard deviation were listed
in Table 3.2.
Figure 3.1f shows that cortical thickness significantly decreased (p<0.05) with age in the
example regions except in superior frontal (p=0.11). Furthermore, 17 out of 26 regions listed in
Table 3.1 showed significant cortical thinning over age with varying rates (slopes, mm/year). But
all slopes are negative, which indicate age-related thinning varied in different regions of the
brain.
Results for the integrated parameter SR2t* were analyzed using the same procedure as OEFrel
and showed no significant linear relationships with age. They were presented using a constant
model demonstrating no significant changes over the studied human lifespans for each ROI
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except caudal anterior cingulate (Figure 3.1g). The mean and standard deviation were listed in
Table 3.2.

ROI
name
banksst
caudal-anterior cingulate
caudal-middle-frontal
cuneus
fusiform
inferior parietal
isthmus cingulate
lateral occipital
lingual
middle temporal
parahippocampal
paracentral
parsopercularis
parsorbitalis
parstriangularis
postcentral
posterior cingulate
precentral
precuneus
rostral-anterior cingulate
rostral-middle-frontal
superior frontal
superior parietal
superior temporal
supramarginal
insula

slope
0.029
0.031
0.034
0.040
0.034
0.034
0.038
0.041
0.048
0.037
0.031
0.043
0.042
0.024
0.033
0.030
0.029
0.037
0.033
0.014
0.020
0.027
0.023
0.038
0.033
0.022

Table 3.1
R2*
intercept
18.6
15.6
17.6
19.7
18.9
18.2
18.3
20.6
19.9
18.5
17.2
19.0
17.0
18.9
17.6
18.3
16.6
18.4
18.0
15.6
17.1
16.6
18.3
17.6
17.6
15.5

Table 3.1 continues on the next page
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pvalue
0.020
0.011
0.006
0.005
0.007
0.002
0.003
0.015
0.005
0.002
0.055
0.001
0.001
0.106
0.010
0.005
0.003
0.003
0.004
0.227
0.074
0.008
0.072
0.002
0.001
0.036

slope
0.028
0.052
0.021
0.043
0.023
0.029
0.044
0.040
0.051
0.030
0.004
0.039
0.042
0.006
0.019
0.032
0.028
0.032
0.034
0.006
0.011
0.027
0.021
0.017
0.028
0.020

R2
intercept pvalue
16.5
0.021
13.5
0.004
15.8
0.120
17.8
0.007
16.4
0.093
16.3
0.012
17.2
0.001
18.1
0.032
18.3
0.009
14.8
0.060
15.0
0.841
17.6
0.027
14.8
0.005
15.1
0.699
15.0
0.392
16.2
0.017
15.2
0.015
16.5
0.020
16.4
0.003
11.9
0.762
14.8
0.417
14.7
0.021
16.1
0.197
14.4
0.275
15.5
0.020
12.5
0.143

Table 3.1 (continue)
ROI
Thickness
name
slope
intercept
banksst
-0.0095
2.51
caudal-anterior cingulate
-0.0018
2.52
caudal-middle-frontal
-0.0052
2.49
cuneus
-0.0035
1.78
fusiform
-0.0064
2.72
inferior parietal
-0.0060
2.39
isthmus cingulate
-0.0030
2.36
lateral occipital
-0.0038
2.18
lingual
-0.0043
2.00
middle temporal
-0.0082
2.86
parahippocampal
-0.0081
2.69
paracentral
-0.0050
2.36
parsopercularis
-0.0081
2.51
parsorbitalis
-0.0039
2.62
parstriangularis
-0.0053
2.36
postcentral
-0.0046
2.03
posterior cingulate
-0.0055
2.45
precentral
-0.0064
2.51
precuneus
-0.0060
2.31
rostral-anterior cingulate
-0.0040
2.76
rostral-middle-frontal
-0.0031
2.23
superior frontal
-0.0047
2.63
superior parietal
-0.0040
2.12
superior temporal
-0.0074
2.77
supramarginal
-0.0073
2.53
insula
-0.0051
3.02

pvalue
0.001
0.617
0.020
0.112
0.002
0.007
0.347
0.023
0.022
0.007
0.036
0.072
0.001
0.228
0.028
0.014
0.016
0.021
0.009
0.212
0.168
0.115
0.094
0.008
0.001
0.002

Table 3.1: The parameters of Equation 3.3 and p-values for R2*, R2t*, and cortical thickness in
26 selected FreeSurfer ROIs across 20 healthy subjects.
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ROI
name
banksst
caudal-anterior cingulate
caudal-middle-frontal
cuneus
fusiform
inferior parietal
isthmus cingulate
lateral occipital
lingual
middle temporal
parahippocampal
paracentral
parsopercularis
parsorbitalis
parstriangularis
postcentral
posterior cingulate
precentral
precuneus
rostral-anterior cingulate
rostral-middle-frontal
superior frontal
superior parietal
superior temporal
supramarginal
insula

Table 3.2
OEFrel
dCBV(%)
mean
std
mean
std
1.14
0.30
3.23
1.22
0.87
0.54
2.79
1.99
1.02
0.20
2.65
0.53
1.10
0.31
2.70
1.69
1.29
0.21
3.36
1.08
1.07
0.22
3.03
0.68
1.02
0.35
1.18
0.90
1.29
0.14
4.25
1.10
1.43
0.42
1.88
1.41
1.05
0.29
6.45
1.59
0.99
0.46
1.86
1.41
1.52
0.52
1.12
0.99
0.98
0.39
3.09
1.29
1.13
0.49
6.12
1.98
0.87
0.36
4.48
2.29
1.21
0.18
2.43
0.88
0.75
0.30
1.88
0.99
1.21
0.17
2.21
0.69
0.89
0.33
2.44
0.89
0.60
0.17
6.25
2.36
0.63
0.20
4.16
1.36
0.75
0.17
2.74
0.62
1.25
0.28
2.80
0.74
0.72
0.22
5.17
1.33
0.89
0.20
3.23
0.94
0.60
0.22
3.46
1.04

Cdeoxy ( µM)
mean
std
18.2
6.0
15.2
10.2
15.5
3.9
14.4
8.5
21.0
5.2
16.5
4.0
6.7
4.5
23.4
5.4
10.5
6.5
37.8
9.0
12.3
8.5
8.1
6.6
17.7
6.1
36.2
9.3
25.1
11.2
15.1
5.7
10.1
5.5
13.7
4.7
13.0
5.0
34.3
11.1
20.9
4.9
15.5
4.3
16.9
5.6
29.1
6.7
17.6
5.1
20.7
6.0

SR2t*(mm/s)
mean std
41.0
3.2
34.3
3.4
39.1
2.7
31.9
3.4
44.4
2.8
38.7
2.5
40.7
3.8
39.6
2.9
36.6
2.8
42.1
3.0
39.8
4.8
41.5
4.3
37.1
2.7
39.5
3.4
35.2
3.9
32.9
2.7
37.1
2.3
41.3
3.4
37.7
2.8
32.9
5.0
33.0
2.7
38.5
3.2
34.2
3.7
39.5
3.8
39.0
2.7
37.8
2.7

Table 3.2: The mean values and standard deviations of the OEF, dCBV, Cdeoxy, and SR2t* in 26
selected FreeSurfer ROIs across 20 healthy subject.
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3.3.2 The Distribution of Parameters on the Brain Surfaces

Figure 3.2 The distributions of all GEPCI-derived parameters are presented on the lateral and
medial cortical surfaces of the left hemisphere, including R2* (s-1), R2t* (s-1), OEFrel,
dCBV(%), Cdeoxy (µM), cortical thickness (Th) (mm), SR2t* (mm/s), and the regression slope (

kROI from Equation (3.3)) of R2t* vs. age (s-1/year). Images for R2*, R2t*, and Th use the
regional characteristic values aROI from Equation (3.3). Images for SR2t*, OEFrel, dCBV and
Cdeoxy use the regional mean values averaged across all subjects (Table 3.1) because they don’t
have a significant linear relationship with age. The surface of the cortex was generated by the
FreeSurfer at the depth of 0.5 (the voxels in the center of gray matter were sampled). White
matter, deep grey matter and ventricles were excluded.
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The distributions of all the GEPCI-derived parameters is presented on the lateral and medial
cortical surfaces of the left hemisphere in Figure 3.2. Images for R2*, R2t*, and Th use the
regional characteristic values

aROI from Equation 3.3. Images for SR2t*, OEFrel, dCBV and

Cdeoxy use the regional mean values averaged across all subjects (Table 3.1) because they don’t
have a significant linear relationship with age. The ventricles, white matter and deep gray matter
are excluded. R2* and R2t* have a similar distributed network. Frontal lobe, inferior parietal,
precuneus and posterior cingulate have relatively lower values than paracentral lobule, lateral
occipital, cuneus and lingual. This distribution feature is consistent with the previously reported
T2* mapping at 7 T resulting from the averaging of 14 subjects (79).

3.3.3 Correlations between Structural and Hemodynamic Cortical Tissue
Properties

Figure 3.3 The correlation and linear regression of (a) R2t* versus cortical thickness; (b) R2t*
versus OEFrel; Each point represents the characteristic value of each FreeSurfer ROIs. The
regional characteristic values of R2t* and thickness correspond to aROI from Equation (3.3).
Since OEFrel remains constant with age in the cortical regions, the characteristic values of OEFrel
are just the mean values across the subjects in the corresponding regions. All the coefficients
from the linear regressions are listed in Table 3.3
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R2t* (s ) vs. Thickness (mm)
R2t* (s-1) vs. OEF

Table 3.3
slope
-3.96
5.09

intercept
25.3
10.5

p value
4.34E-05
6.94E-07

r
0.71
0.8

Table 3.3: The regression coefficients, p values and Pearson correlation coefficients for R2t* vs.
Thickness and R2t* (s-1) vs. OEFrel. Data represent averages from 20 healthy subjects across 26
selected FreeSurfer ROIs displayed in Figure 3.3.

The regional characteristic values of R2t* and thickness correspond to

aROI from Equation (3.3).

Since OEFrel remains constant with age in the cortical regions, the characteristic values of OEFrel
are just the mean values across the subjects in the corresponding regions. R2t* correlates
negatively with the cortical thickness across 26 cortical ROIs (p < 0.05 and r = 0.71, Figure
3.3a). This correlation indicates that the thinner cortex has a relatively higher R2t*. Furthermore,
R2t* positively correlates with OEFrel across 26 cortical ROIs (p < 0.05 and r = 0.8, Figure 3.3b).
The regions extracting more oxygen also have higher R2t*. Implications of all these correlations
will be discussed in detail in the Discussion section.

3.3.4 Age-related Changes of R2* in Subcortical Regions
Table 3.4
ROI
name
caudate
putamen
pallidum
thalamus
hippocampus
amygdala

slope
0.094
0.209
0.178
0.013
0.024
0.035

R2* (s-1)
intercept
21.4
24.0
34.8
21.0
16.9
15.4

p value
0.0003
0.0003
0.0004
0.1635
0.0816
0.0341

Table 3.4: The regression coefficients and p values of R2* vs. age in 6 subcortical ROIs. Data
represent results from 20 healthy subjects displayed in Figure 3.4.
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Figure 3.4 The scatter plots and linear regressions of R2* versus age in subcortical ROIs. Each
plot represents the data from a single subcortical region and each point in the plot represents the
median value in the region from a single subject. Male subjects are represented by blue points
and female subjects by red points. The solid lines are the regression curves and the dashed lines
are the 95% confidence intervals. All the coefficients from the linear regressions are listed in
Table 4. p < 0.001 ***, p < 0.01 **, p < 0.05 *.

R2* significantly increases with age in basal ganglia (caudate, putamen and pallidum), and
amygdala. Thalamus and hippocampus show less significant age-related changes. Notice that
R2* in the basal ganglia is substantially larger than R2* in the cortex. This is because basal
ganglia is rich of iron deposition, which is paramagnetic and cause R2* to increase significantly.
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3.2.5 Error Analysis

Figure 3.5 The histograms of the simulated data for R2t*, OEF, dCBV and C deoxy are shown
with true values (black) and median values (red). The black and red lines overlap in the
histogram of OEF. Note that the peak in OEF histogram at the lower boundary is due to the
restriction set in the fitting routine (OEF > 10%).

true values
median
mean
standard deviation

A0
100.00
99.94
99.85
0.75

Table 3.5
R2t* (s-1)
17.00
16.91
16.44
2.06

OEF (%)
40.00
40.01
40.80
17.32

dCBV (%)
3.00
3.43
4.12
2.60

Cdeoxy ( µM)
22.44
24.63
27.04
10.73

Table 3.5: The true values, medians, means and standard deviations of all the parameters in the
simulations are listed here. The medians more accurately represent true values than the means for
all the parameters.
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The results are listed in Table 3.5. The histograms of the output parameters, and the
corresponding true and median values are shown in Figure 3.5. The results show that the median
values of R2t*, OEF, dCBV and Cdeoxy better represent the true values than the means because
the histograms are skewed and the median is less biased by the outliers.

Figure 3.6 The contour covariance maps of the simulated data. The results show the peak values
of R2t* around 17, OEF around 40% and dCBV around 3%, well estimating the true values. The
covariance between OEF and dCBV is consistent with the actual covariance map between the
OEF and dCBV presented in Fig. 6 in the previous publication by Ulrich and Yablonskiy (5).

The 2D contour covariance maps of the relationships between R2t*, OEF and dCBV are shown
in Figure 3.6. It demonstrates the peak value of R2t* around 17, OEF around 40% and dCBV
around 3%, well estimating the true values. The negative correlation between R2t* and OEF (r =
-0.88, p < 0.001) strengthens that the observed positive correlation between R2t* and OEFrel in
our experimental data (Figure 3.3) reflects the physiological relationship instead of errors.
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Figure 3.7 Typical example of the distribution of F(TE10) and the joint covariance contour of
R2t* and F(TE10) are shown for a single subject. The range of F(TE10) is from 0 to 1 and most of
values are between 0.9 to 1. The number of voxels with F(TE10) lower than 0.8 is quite small and
they are not visible on the contour map. No covariance is found between R2t* and F(TE10)
suggesting no bias in R2t* estimate due to the field inhomogeneities.

The detailed analysis of the correction for field inhomogeneity artifacts was provided in
Yablonskiy lab’s previous paper where voxel spread function method (3) was introduced. Here
we further demonstrate that VSF procedure does not create bias in parameters estimates in our
data. The signal decay due to the macroscopic field inhomogeneities is characterized by the F
function at the last echo, F(TE10), where the strongest signal decay is observed. Example of the
distribution of F function at the last echo, F(TE10), and the contour map of the joint covariance
between R2t* and F(TE10), for the whole gray matter from an individual subject is shown in
Figure 3.7. No correlation is found between R2t* and F(TE10). The peak value of F(TE10) is
around 0.99 and most of values are located between 0.9 and 1 due to a good shimming procedure
and rather small voxel size. The number of voxels with values lower than 0.8 is so small that
they are not visible on the contour map. These voxels with lower F(TE10) are mostly affected by
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the magnetic inhomogeneity due to the air/water interface around the sinuses and represent a
very small fraction of the brain.
One additional bias in the parameter estimates may be related to the estimation of OEF. Because
the BOLD model is developed under the assumption that the orientations of blood vessels are
statistically random in each voxel, the actual variations of the blood vessel orientations may
cause deviations in estimating OEF on a voxel by voxel basis. For example, if the blood vessels
in some voxels have the predominant orientation parallel to the static magnetic field B0, the
BOLD effect is so minimal that the fitting routine will substantially underestimate OEF;
conversely, OEF will be underestimated for the voxels with the predominant orientations of
blood vessels perpendicular to B0. However, as demonstrated in (8), the estimates of R2t* and
dCBV are not affected by this limitation. Besides, the use of median values for representing our
results for very large regions, also minimizes these biases.
In conclusion, although substantial deviations from the true values of all parameters can be found
in individual voxels and there are several restrictions on this model, the medians values of the
parameters are very close to the true values. All in all, the simulations support that the
methodology used in this study can generate the valid regional medians of R2t* and
hemodynamic parameters for large cortical regions. In my dissertation, the results in cortical
regions usually contain thousands of voxels.

3.4 Discussion
The result section shows the relationship between GEPCI derived parameters and age across
cortical ROIs, which achieve the first goal of this study. The second goal is to interpret these
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results and find out the biological meaning of GEPCI derived parameters, especially for R2* and
R2t*. The key questions are: why R2t* increases with age in the cortex and what features of the
brain cellular structure cause this increase and variability between different brain structures?
Main contributions to R2t* signal decay in different brain structures come from the water
molecules interactions with cell structural proteins, lipids and iron (80-82). In the subcortical
GM, i.e., the caudate, putamen and pallidum, a significant increase in R2* with age that we
observed (Fig. 4), is consistent with previous studies (82-87) and is usually attributed to the
known iron deposition in those regions with the increasing age. However, iron is unlikely a
contributor to the age-related increase of the cortical R2t* because, according to Hallgren and
Sourander (88), the iron content in the cortex remains nearly constant after the age of 30. The
major contributions to the increased cortical R2t* and its variability are likely to be attributed to
the water molecule interactions with other cellular structural components such as lipids and
proteins.
Another source of the variation in R2* potentially could be an anisotropic effect reported by
Rudko et al (89). However, even at 9.4T field strength, R2* showed only 0.94 ± 0.32 s-1
variation in GM of mice, which is a much smaller effect than the variation across different brain
regions that we found in a human brain at 3T.
The hypothesis that the changes of MR signal relaxation properties are related to the changes in
the concentration of lipids and proteins has been useful in studying Central Nervous System
(CNS) diseases, such as Multiple Sclerosis (e.g., (69, 90)) where cellular damage is mostly
attributed to the loss of myelin. However, this hypothesis might not be adequate to describe
normal aging effects of a healthy tissue where MR signal relaxation properties are related not
only to the concentration of the cellular structural components but also to their cellular structural
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arrangements (91). For example, lipids distributed as multiple small droplets would have much
bigger water-accessible surface, hence cause substantially stronger relaxation effects than a
single large lipid droplet with the same total amount of lipids.
Herein by comparing our results with the literature data about normal aging (reviewed in Chapter
2) we provide support for a hypothesis that in a healthy adult brain the tissue-specific R2t* can
serve as a biomarker of the cortical “cellular packing density”, which is mostly proportional to
the number of neurons and glial cells in the unit tissue volume. We also use this hypothesis to
explain the relationships between R2t* and the functional data, such as OEF and aerobic
glycolysis.

3.4.1 Cortical Cellular Packing Density is related to R2t*
Our hypothesis is supported by the available literature data on the cellular changes in the aging
brain. As reviewed in Chapter 2, it was a common impression that the neuron loss (20, 21) is an
inevitable process of aging that leads to the cortical thinning and cognitive dysfunction.
However, many studies have reported that the number of neurons in the human cortex remains
the same over adult life (19, 22-26, 35, 92) and that normal aging is accompanied by changes in
the dendritic structures, spine density and synapse density. Even the total number of glial cells in
the cortex remains relatively constant over normal adult life (25, 27). The unchanged number of
cells and the decreasing cortical volume imply the increasing cell density with age in the cortex,
which is also supported by previous studies (23, 26, 31).
This increasing age-related cortical cellular packing density in the cortex is consistent with our
interpretation of age-related increased R2t* reported herein as a biomarker of cellular packing
density. In this context, the product of R2t* and cortical thickness, SR2t*, represents the cellular
packing content underneath a unit surface (e.g., 1 square millimeter surface) of the cortex. Our
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finding that this product remains constant with age for all cortical regions (Figure 3.1g, Table
3.1), is in agreement with the preservation of cortical cellular content in healthy adults over age.
If both the number of neurons and the relative fraction of glial cells to neurons stay the same
over age, the density of both neurons and glial cells would go up proportionally. Since axons and
dendrites contain considerably larger concentration of macromolecules (e.g., lipids and proteins),
their contribution to the R2t* relaxation is expected to be prevailing compared to glial cells even
though concentration of glia cells in the cortex is higher. Hence, we hypothesize that the increase
of R2t* is mainly due to the increased neuronal density.

3.4.2 Neuronal Density of Non-human Primates is related to R2t*
Our data is also compared with the neuronal density of non-human primates measured by Collins
et al. (93). Collins et al. reported the highest neuronal density in primary visual cortex, the
second highest in association visual areas and relatively higher density in primary somatosensory
areas (S1) among all of the examined primates. Lowest neuronal densities were found in
prefrontal cortex, premotor cortex or cortex ventral to S1 and motor cortex (M1) in different
primates. Those distributions of neuronal density are in a good association with the distributions
of R2t*. Indeed, the highest R2t* were found in the visual cortex (cuneus, lateral occipital and
lingual) and the lowest were found in the frontal areas (Figure 3.2 and Table 3.1). Relatively
higher R2t* were also shown in S1 and M1 (paracentral, precentral and postcentral) and R2t*
values in these two regions were similar. Relatively lower R2t* were found in regions close to
S1 and M1. All in all, these data further support our hypothesis that R2t* is related to neuronal or
cellular packing density.
Elston et al. (94) found that cells in the prefrontal cortex of humans are more branched and more
spinous than those in the temporal and occipital lobes. Comparing these results with the
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measurements of neuronal density by Collins et al. (93) we can conclude that regions with
relatively lower neuronal density have more complex dendritic arbors, larger somas and dendritic
field sizes and more spines than regions with higher neuronal density. This is in agreement with
the line of consideration by Glasser and Van Essen (95) who utilized T1- and T2-weighted MRI
to evaluate a distribution of the myelin content in the cortex. Hence, comparing the R2t* maps
with these literature data (93, 94), we can further suggest that the areas with lower R2t* represent
regions with complex dendritic arbors, larger somas and dendritic field sizes and more spines
than regions with higher R2t*.

3.4.3 Brain Tissue Hemodynamic Properties
Besides R2t*, the relative OEF, dCBV and Cdeoxy are also derived from GEPCI data and they are
in agreement with previous literature results. The distribution of the relative OEF in Figure 3.1
shows the uniformity across frontal area and precuneus but higher values in the visual cortex
(cuneus and lingual) which is consistent with the findings of default mode network (96). The
relative OEF shows no significant change with age (Figure 3.2c), which is consistent with
previous studies. Leenders et al. reported that oxygen extraction fraction (OER) didn’t change or
showed a slight increase with age in the selected regions (97). Pantano et al. showed that OEF
had no statistically significant changes with age, although a small upward trend was present (98).
Yamaguchi et al. also demonstrated that OEF didn’t show any correlation with age (99). GEPCI
dCBV shows no significant change with age which is consistent with previous findings of no
significant changes in the cerebral blood volume (which is a measure of both, dCBV and arterial
blood volume) with age (97, 99).
The R2t* map outlines practically the same pattern as the map of aerobic glycolysis (100) with
areas of low R2t* corresponding to areas of high aerobic glycolysis and areas of high R2t*
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corresponding to areas of low aerobic glycolysis. This fits well with our biophysical hypothesis
of R2t* reflecting cellular packing density. Indeed, the areas of complex dendritic and synaptic
structures characterized by lower R2t* are likely to require high aerobic glycolysis needed to
support high synaptic activities (101). Moreover, since the correlation in brain regions between
aerobic glycolysis and CBF is stronger than that between aerobic glycolysis and CMRO2 (101),
areas of high aerobic glycolytic activity may show relatively lower OEF. Hence, it explains the
strong correlation between R2* and OEF (p < 0.001, r = 0.71 in Figure 3.2b). It is also important
to note that the regions with lower R2t* are mostly located within the default mode network (96).
Although OEF and R2t* are derived from the same data and model, their correlation is robust.
Computer Monte-Carlo simulations (15) demonstrated that bias in the estimation of R2t* due to
using static dephasing regime model (11) does not exceed 0.3 s-1 and biases in OEF and dCBV
are smaller than 10%. Furthermore, Figure 3.6 shows that the correlation between R2t* and
OEFrel is negative due to the noise of the data and fitting routine. Hence, the observed positive
correlation is due to the biological environment in the human brain. Besides, the results are
consistent with the above listed literature data.

3.4 Summary
Distinguishing the cognitive changes of normal aging from the initial stages of
neurodegenerative disorders, such as Alzheimer’s disease, can be difficult. Hence, establishing
baseline MRI biomarkers for normal aging is significant and valuable. In this study, we used an
advanced GEPCI approach (3-5) allowing the quantitation of various tissue specific structural
and functional metrics.
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Comparison between GEPCI data and the available literature information suggests that the agerelated increase in the cortical R2t* mostly reflect the age-related increase in the cellular packing
density. GEPCI data also show that tissue hemodynamic parameters, i. e. relative OEF, dCBV
and Cdeoxy have no linear correlations with age and remain practically constant in most cortical
regions. We found important correlations characterizing relationships between brain structural
and hemodynamic properties in different brain regions. Specifically, thicker cortical regions have
lower R2t*, reflecting less cellular packing density, and these regions extract less oxygen from
the blood.
All our findings can be understood if we put forward the following hypotheses:
1. Regions in a brain characterized by a higher R2t* contain higher concentration of neurons
with less developed cellular processes and are characterized by lower glycolytic activity.
Accordingly, they require less blood flow to maintain their structure. These areas have higher
OEF.
2. Regions in a brain characterized by a lower R2t* represent regions with lower concentration of
neurons but more developed cellular processes (dendrites, spines, etc.). They display higher
glycolytic activity, hence require higher blood flow to maintain and develop new structural
elements responsible for “information storage”. These areas have lower OEF.
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Chapter 4: In vivo Detection of
Microstructural Correlates of Brain
Pathology in Preclinical and Early
Alzheimer’s Disease with MRI
4.1 Introduction
Based on the biological interpretations of GEPCI metrics in Chapter 3, we now apply GEPCI
metrics to Alzheimer’s disease (AD). As reviewed in Chapter 2, Alzheimer’s disease (AD) is a
neurodegenerative disorder that is characterized by intraneuronal aggregates of tau called
neurofibrillary tangles and extracellular aggregates of amyloid-beta (Aβ) protein called plaques.
Clinically, AD is characterized by memory deficits and progressive cognitive impairment,
leading to dementia. The preclinical stage of AD provides a large window for therapeutic
intervention (102). Hence, one of the important directions is developing widely accessible
neuroimaging techniques that can detect AD brain pathology in the preclinical stages (103, 104).
One of the prevailing hypotheses of AD is the amyloid cascade hypothesis (36, 39, 41, 42) that
suggests that abnormal accumulation of (Aβ) in the neocortex is one of the earliest pathological
markers of AD. Paradoxically, it is also known that the medial temporal lobe (MTL), a region
that mediates short-term memory, is affected early in the disease but is not the most affected
region by Aβ deposition compared with neocortical regions (e.g., prefrontal cortex and precuneus
(47-49)). At the same time, histological studies show that the MTL is particularly vulnerable to
neurofibrillary pathology in the early stages of aging and AD (65, 66, 105-108). The reduction of
volume and the loss of cells in the entorhinal cortex and hippocampus have been extensively
reported in participants with mild cognitive impairment (MCI) and AD (57-61). Importantly,
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neuropathology studies have established that symptomatic AD begins only when cell loss occurs
in the hippocampal area (59).
MRI is a potentially powerful tool to identify changes in the Alzheimer brain. Most MRI studies
so far have focused on AD-related volumetric measurements of brain atrophy

(109). A few

studies attempted to identify plaques via MRI in postmortem specimens or mice models (110115), though the latter methods require long imaging time and have not been translated to human
studies.
The goal of this study was to establish the relationship between GEPCI metrics and AD-related
tissue damage at preclinical and very early symptomatic stages of AD. To this end, participants
were enrolled from the Washington University Knight Alzheimer’s Disease Research Center
(Knight ADRC) with well-characterized clinical status ranging from cognitively normal to very
mild and mild AD, and with a battery of psychometric, CSF and neuroimaging data. We
demonstrated a significant correlation between GEPCI metrics of brain tissue cellular damage in
the hippocampus and cognitive performance. Importantly, this correlation is stronger than the
correlation between cognitive performance and hippocampal atrophy, thus suggesting that the
integrity of the remaining tissue is a more important parameter for brain functioning than the loss
of tissue volume alone. We also uncovered a remarkable correlation between GEPCI metrics and
beta-amyloid load measured by positron emission tomography (PET) (the current in vivo gold
standard), thus supporting GEPCI as a potential surrogate marker for Aβ imaging in preclinical
and early Alzheimer disease.
The results demonstrate that GEPCI is sensitive to early AD-related pathological changes in
brain tissue. Since the GEPCI approach is based on MRI that is widely available worldwide, is
non-invasive, and does not require radiation exposure, it can open opportunities to obtain new
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information on the pathogenesis of AD. The new method can also open the door for screening
cohorts for clinical drug trials (stratification) that are enrolling individuals with preclinical or
early symptomatic AD.

4.2 Methods
4.2.1 Participants
This study was approved by the Institutional Review Board of Washington University School of
Medicine (WUSM). 34 participants were selected from the studies of aging and dementia at the
Knight Alzheimer’s Disease Research Center (ADRC) at WUSM. All participants provided
informed consent. All participants in this study underwent a collection of cognitive performance
tests (116), including Free and Cued Selective Reminding Test (Srtfree), Animal Naming
(ANIMALS), and Trail making Test Part A (Tma) . Cognitive status was operationalized with
the Clinical Dementia Rating (CDR) (67), as determined by Knight ADRC clinicians according
to standard protocols; diagnoses were in accordance with standard criteria (38). The participants
were assessed to be cognitively normal (CDR = 0) or to have mild (CDR = 0.5 or 1) AD
dementia. 19 participants underwent PiB PET imaging to estimate amyloid deposition in the gray
matter and white matter of their brains. The measurements of CSF biomarker Aβ42 (INNOTEST,
Fujirebio, Gent, Belgium) were available for 31 participants. For participants that underwent PiB
PET imaging, amyloid positivity was defined by a cutoff of mean cortical binding potential
(MCBP)=0.18 (117) which corresponds to a mean cortical standardized uptake value ratio (MCSUVR) of 1.3 referenced to cerebellar grey matter. MC-SUVR for Aβ imaging is calculated as
the averaged SUVR of regions within the prefrontal cortex, gyrus rectus, lateral temporal, and
precuneus regions. For participants that did not have PET Aβ measurements, Aβ positivity was
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determined by the status of their CSF biomarker Aβ42 (103). According to the Aβ status,
cognitively normal participants (CDR = 0) were further divided into normal (CDR = 0; Aβ
negative) and preclinical (CDR = 0; Aβ positive) groups. Notice that one participant with CDR =
0.5 and one with CDR = 1 had negative Aβ status. Demographic information for all groups is
presented in Table 4.1.

N
Age
Female/Male

Table 4.1
Normal
Preclinical AD
CDR=0
CDR=0
Aβ negative
Aβ positive
13
10
69.6±8.7
72.3±8.4
7/6
4/6

Mild AD
CDR=0.5
or 1
11 (7/4)
76.0±8.4
3/8

Table 4.1 Distribution of participants between groups and their demographic information. Note
that nine participants in Mild AD group were Aβ positive and two were Aβ negative.

4.2.2 MRI Data Acquisition
All participants were scanned in a 3T PET-MR scanner (Siemens, Erlangen, Germany). A 3D
multi gradient echo sequence was used to obtain the data. Sequence parameters were: resolution
1×1×2 mm3 (read, phase, slab), FOV 256 mm×192 mm, repetition time TR = 50ms, flip angle
30°, 10 gradient echoes with first gradient echo time TE1 = 4 ms, echo spacing ∆TE = 4ms.
Additional phase stabilization echo (the navigator data) was collected for each line in k-space to
correct for image artifacts due to the physiological fluctuations (4). The total acquisition time of
GEPCI was 11 mins 30s. Macroscopic field inhomogeneity effects (background gradients) were
accounted for by using the voxel spread function (VSF) approach (3). Standard clinical
Magnetization-Prepared Rapid Gradient Echo (MPRAGE) (75) images with TR/TI/TE =
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2200/1100/3.37 ms and the resolution 1×1×1 mm3 were also collected for segmentation
purposes. The total acquisition time of MPRAGE is 6 mins.

4.2.3 Data Analysis and GEPCI Images Generation
This part was the same as Chapter 3, which was described in details in Chapter 1. Herein, I
briefly introduce the model and fitting parameters:
S (TE )  A0  exp   R 2*  (TE  TE1 )  i  2  f  (TE  TE1   F (TE )
S (TE )  A0  exp   R 2t *  (TE  TE1 )  i  2  f  (TE  TE1 )   FBOLD (TE )  F (TE )

(4.1)

where TE is the gradient echo time, R2*=1/T2* is the global transverse relaxation rate constant,
R2t*=1/T2t* is the tissue transverse relaxation rate constant in the absence of BOLD effect, Δf is
the frequency shift (dependent on tissue structure and also macroscopic magnetic field created
mostly by tissue/air interfaces), function

FBOLD (TE ) describes GRE signal decay due to the

presence of blood vessel network with deoxygenated blood, and function F(TE) describes the
effects of macroscopic magnetic field inhomogeneities.
By fitting the equation to the real and imaginary parts of the complex signal using nonlinear
regression algorithm, six parameters are computed: A0 (T1-weighted), R2*, R2t*, Δf,  and 
for each voxel in the brain. In this study, we focus on total R2* and tissue specific R2t*
measurements for quantifying tissue microstructural properties and GEPCI T1W images (the
square root of parameter A0) for brain structure delineation and segmentation.
Notice that

FBOLD (TE ) in Equation 4.1 was originally designed to describe the signal decay due

to the presence of different types of magnetic susceptibility inclusions, such as blood vessel
network (BOLD effect), trabecular bone and iron oxide nanoparticles, etc. (11). It has different
formulas for different inclusions and the one we used in this study is modeled for the blood
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vessel network. But in the context of AD,

FBOLD (TE ) may also include the mesoscopic

inhomogeneity effects created by amyloid plaques that are known to create R2* signal decay
(115). As a result, R2* is more related to the amyloid deposition while R2t* is more related to
the tissue structure.

4.2.4 Image Segmentation
The segmentation part is also the same as Chapter 3. FreeSurfer software (Laboratory for
Computational Neuroimaging, Martinos Center for Biomedical Imaging) (76) was used to
generate brain segmentations, cortical thicknesse and volume based on MPRAGE images. Then,
MPRAGE images are registered to GEPCI-T1-weighted (T1W) images using FMRIB’s Linear
Image Registration Tool (77, 78) in FSL and the transformation matrices of the registration are
generated. Finally, these matrices were applied to the brain segmentations from FreeSurfer and
transformed to the space of GEPCI-T1W images. One of the important advantages of GEPCI is
that all GEPCI images are generated from a single MRI scan and are naturally co-registered.
Hence, segmentations of GEPCI T1W images were naturally co-registered with all other GEPCI
maps.
A CSF mask from FSL is further applied removing voxels in CSF on FreeSurfer segmentations.
To maximize accuracy of measurements, statistical results instead of voxel-wise analysis are
reported: for each FreeSurfer region containing thousands of voxels, a single parameter – mean
value of GEPCI parameter, is generated.

4.3 Results and Discussions
In the context of AD, we hypothesize that the increased beta-amyloid deposition should lead to
an increase in GEPCI R2* that is sensitive to mesoscopic field inhomogeneities (8, 11). The
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mesoscopic field inhomogeneities may be present around amyloid deposits and can be enhanced
due to the presence of iron in amyloid plaques (111). On the other hand, cellular loss
characteristic of AD can lead to decreased GEPCI metrics, especially R2t* that is sensitive to
cellular structure (12). The interplay between these two opposing processes can define important
features of the GEPCI signal in AD.

4.3.1 Correlation between R2* and PiB-PET Aβ Measurement

Figure 4.1 Correlation between PiB PET Aβ SUVR (dimensionless) and R2* (s-1) relaxation rate
constant obtained in 19 participants. Plots show examples of correlation in several brain regions.
Each point represents a single participant. Shaded areas represent 95% confidence intervals of
the linear fits (solid lines). Pearson correlation coefficients (r) and p values (corrected for
multiple comparison using false discovery rate over all cortical regions) are shown in the left
upper corners. The surface maps on the right represent r values in all cortical areas. The image
segmentation is based on the FreeSurfer software (76). The data show significant correlations not
only in the areas of high Aβ accumulation (e.g., precuneus) but also in the areas of MTL, such as
the parahippocampal cortex and the fusiform cortex. Particularly, the strongest and most
significant correlation exists in the parahippocampal cortex.

The correlation analysis between R2* and PiB PET Aβ measurements (using standardized uptake
value ratio [SUVR]) revealed positive correlations in most cortical brain regions. The data
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showed significant correlations not only in the areas of high Aβ accumulation (e.g., precuneus)
but also in the areas of MTL, such as the parahippocampal cortex and the fusiform cortex. But
not all correlations were statistically significant after correction for multiple comparison using
false discovery rate (FDR) (118), most likely due to the small sample size (PiB PET data were
available only for 19 participants). Examples of the correlations with significant p values are
shown in Figure 4.1.
The strongest correlation between R2* and Aβ SUVR that we found in the parahippocampal
cortex shows the high sensitivity of GEPCI R2* to Aβ accumulation in this area. Interestingly,
although the range of SUVR in parahippocampal cortex is smaller than in precuneus, the
correlation in parahippocampal cortex is much stronger than that in precuneus. It indicates that
even though MTL is not the area of the highest burden of Aβ in the AD brain, it represents a very
important area of pathological changes in early AD particularly as it relates to the formation of
Aβ plaques in the cerebral cortex, where the changes can be detected by GEPCI R2*. This
feature likely can be attributed to distinct cellular properties of the gray matter in the MTL that
play important roles in functionally connecting the neocortex and hippocampus (119).
Structurally, the parahippocampal gyrus is a transitional zone, where the entorhinal cortex
(referred as perialocortex) contains the lamina dissecans while the perirhinal and
parahippocampal cortexes (referred as proisocortex) have their cellular structure different from
the major three-layered and six-layered cortex areas (120). As different cellular components and
arrangements contribute to R2*, it is possible that the strong correlations between R2* and Aβ
SUVR in the parahippocampal cortex is due to its unique laminar organizations. Since the medial
portion of the fusiform gyrus is also considered to be part of the parahippocampal cortex, it is
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reasonable to observe the significant correlation between R2* and Aβ SUVR in the fusiform as
well.
How can we interpret the correlation? As we discussed in Methods,

FBOLD (TE ) may also include

the mesoscopic inhomogeneity effects created by amyloid plaques that are known to create R2*
signal decay (115). Since no correlation exists between amyloid accumulation and BOLD effect
(100), the correlation between amyloid accumulation and R2* is mostly related to magnetic
susceptibility effects created by amyloid plaques. A hypothesized iron deposition in amyloid
plaques (111, 121) could lead to additional sensitivity of GEPCI R2* to Aβ accumulation.
The presence of neurofibrillary tangles (NFTs) and neuronal loss in the parahippocampal gyrus
previously reported by Thangavel et al (65) can also affect R2*. However, their participants were
assessed at death after nearly a decade of dementia, while the cohort in this study represents
mostly normal, pre-symptomatic, very mild (CDR = 0.5) or mild (CDR=1) AD. In addition, as
tissue damage in the parahippocampal gyrus was smaller than that in the hippocampus (66), in
our cohort the loss of neurons in the parahippocampal gyrus may not be severe enough to affect
R2* measurements.
Even though the significance of the correlations between R2* and Aβ SUVR vary for different
brain regions, R2* in the parahippocampal cortex can still be used for evaluation of Aβ burden in
all regions. Indeed, the data show very strong correlations between Aβ SUVR in most cortical
regions and R2* values in the parahippocampal cortex. These correlations can be described as
follows:
*
SUVRROI  aROI  kROI  ( R2*PH  R 2PH
)
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(4.2)

and can be used for evaluation of Aβ SUVR for a given participant in any cortical region. In
*

*

*

Equation (4.2), R 2PH is R 2 in the parahippocampal cortex for a given participant, and R 2PH =
16.55 sec-1, is the mean value of R2* in the parahippocampal cortex of the normal control group
(9 participants with negative PiB Aβ and CDR = 0). The coefficients

aROI and kROI in Equation

(4.2), specific for each cortical ROI, are provided in Table 4.2 along with the results of the
*

correlations. R 2PH is introduced in Equation (4.2) to make the coefficients

aROI of the regression

more meaningful – they represent region-specific averaged SUVR for healthy control group. The
slopes of the regression (parameter

kROI ) are also shown in Figure 4.2, upper row. The spatial

pattern in Figure 4.2 is similar to previously established correlation pattern between regional and
mean values of PiB SUVR (122). Hence, the data demonstrate that R2* in the MTL (especially
the parahippocampal cortex) not only correlate with PiB PET SUVR in this area but also
strongly correlate with PiB PET SUVR throughout the entire cortex.
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Table 4.2
Cortical area
Intercept (a) Slope (k, sec)
p value
r
bankssts
1.35
0.24
2.47E-04 0.75
caudal-anteriorcingulate
1.23
0.27
2.45E-04 0.75
caudal-middlefrontal
1.16
0.24
1.76E-04 0.76
cuneus
1.22
0.12
2.79E-02 0.50
entorhinal
1.10
0.08
1.33E-04 0.77
frontalpole
1.07
0.30
5.31E-04 0.72
fusiform
1.21
0.15
2.02E-04 0.75
inferiorparietal
1.21
0.23
4.08E-04 0.73
inferiortemporal
1.15
0.20
4.63E-04 0.72
insula
1.23
0.18
2.90E-04 0.74
isthmuscingulate
1.34
0.25
5.46E-04 0.72
lateraloccipital
1.15
0.12
1.22E-03 0.68
lateralorbitofrontal
1.26
0.25
4.45E-04 0.72
lingual
1.19
0.12
6.46E-03 0.60
medialorbitofrontal
1.23
0.32
2.98E-04 0.74
middletemporal
1.13
0.21
1.73E-04 0.76
paracentral
1.21
0.23
1.00E-03 0.69
parahippocampal
1.11
0.15
6.09E-06 0.84
parsopercularis
1.19
0.23
4.66E-04 0.72
parsorbitalis
1.13
0.26
4.97E-04 0.72
parstriangularis
1.20
0.24
3.90E-04 0.73
pericalcarine
1.27
0.14
2.56E-02 0.51
postcentral
1.07
0.15
2.02E-03 0.66
posteriorcingulate
1.29
0.32
4.58E-04 0.72
precentral
1.14
0.14
9.57E-04 0.70
precuneus
1.30
0.32
5.93E-04 0.71
rostralanteriorcingulate
1.23
0.31
2.28E-04 0.75
rostralmiddlefrontal
1.16
0.30
4.34E-04 0.73
superiorfrontal
1.14
0.28
3.25E-04 0.74
superiorparietal
1.15
0.21
6.31E-04 0.71
superiortemporal
1.15
0.18
2.45E-04 0.75
supramarginal
1.16
0.21
6.68E-04 0.71
temporalpole
1.11
0.10
9.94E-04 0.69
transversetemporal
1.21
0.18
4.48E-04 0.72
Table 4.2. The results of linear regression analysis of the relationship between regional amyloid
SUVR in different cortical regions and the parahippocampal R2*. Cortical regions are selected
based on the FreeSurfer segmentation (76). The data show coefficients of linear regression in
Equation (4.2) and the correlation coefficients (r). The mean value of R2* in the
parahippocampal region for the control group in Equation 4.2 is 16.55 sec-1.
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Figure 4.2 Upper row represents the surface maps of the slopes (units of sec) of linear regression
(coefficient k ROI in Equation (4.2)) between regional PET-measured Aβ SUVR and
parahippocampal R2* across 19 participants. All regional slopes are positive. The coefficients of
the linear regressions are listed in Table 4.2. The second and the last rows represent the averaged
cortical mean values of R2* and Aβ SUVR across the same 19 participants. White matter, deep
gray matter and ventricles were excluded. The image segmentation is based on the FreeSurfer
software (76).

While the data show rather significant positive correlations between R2* and amyloid burden
across the participants in different brain regions (Figure 4.1), there also exists an inverse
association across the brain regions between averaged R2* and amyloid distributions. Figure 4.2
shows regional R2* and Aβ SUVR averaged across 19 participants mapped onto the brain
surface. Lower R2* are found in the frontal cortex, posterior cingulate, precuneus,
parahippocampal cortex, entorhinal cortex and superior temporal cortex. Higher R2* are found in
the occipital cortex, paracentral cortex, fusiform, middle and inferior temporal cortex. This R2*
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distribution is consistent with the previous studies (12). In contrast to the R2*, the PiB retention
was prominently higher in the frontal cortex, posterior cingulate, precuneus and inferior parietal
cortex, which is also consistent with the previous reports (44, 47). Generally speaking, PiB Aβ
binding tends to increase in the regions with lower R2*, which may indicate that the regions with
lower R2* are more vulnerable to the amyloid accumulation. This relationship is more obvious
in the frontal cortex, posterior cingulate, precuneus, inferior parietal cortex characterized with
higher SUVR but lower R2*, and occipital cortex with lower SUVR but higher R2*.
Interestingly, the former regions mostly overlap the default mode network (96) and tend to be
both structurally and functionally vulnerable in normal aging and Alzheimer’s disease, which
was suggested to be due to a high degree of life-long plasticity (32). The R2*- Aβ association
points to an important relationship between brain microstructural properties reflected in tissue
specific R2* measurements and the relationships between default activity, amyloid, and memory
previously reported by Buckner et al (123). It is also in agreement with our previous
consideration (12) that the cortical areas with lower R2t* (e.g., prefrontal cortex) may have more
complex dendritic and synaptic structure, which may also be related to the neuroplasticity and
AD vulnerability. From this perspective, the parahippocampal and entorhinal cortices, which are
primary memory-related areas and are vulnerable to early Alzheimer, are also characterized by a
lower baseline R2*. However, PiB retention and Aβ accumulation in these areas are not
prominent. Nevertheless, the correlation between GEPCI R2* metrics and PiB retention in these
areas is exceptionally strong, especially in the parahippocampal gyrus.
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4.3.2 R2* Differentiates Normal and Preclinical AD Participants

Figure 4.3 Group comparison based on R2* in the parahippocampal cortex. The bar graph on the
left shows significant differences between participants with the negative (n = 15, R2* = 16.79 ±
1.40 s-1) and the positive (n = 19, R2* = 18.20 ± 1.08 s-1) Aβ status. The bar graph on the right
shows significant differences between the normal group (CDR = 0, Aβ negative, n=13, R2* =
16.77 ± 1.51 s-1) and the preclinical group (CDR = 0, Aβ positive, n = 10, R2* = 18.41 ± 0.84 s1
).
Based on the strong correlation between Aβ SUVR and R2* in the parahippocampal cortex, R2*
can potentially be used to distinguish the healthy stage from the preclinical AD as early AD is
associated with Aβ accumulation (36, 39, 41, 42). Indeed, the bar graph on the left in Figure 4.3
shows a significant difference in the parahippocampal R2* between all participants with negative
(n = 15) and positive (n = 19) Aβ status (independent of CDR, see definition in Methods). The
bar graph on the right shows significant differences between normal group (CDR = 0, amyloid
negative, n=13) and preclinical group (CDR = 0, Aβ positive, n = 10).

4.3.3 Correlation between R2t* and Cognitive Performance Tests
In Chapter 3, we compared GEPCI-derived tissue specific structural and functional metrics with
existing literature and hypothesized that the parameter R2t* is related to the tissue neuronal
density (12). As presented in the scatter plots in Figure 4.4, R2t* in the hippocampus was
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associated with the free recall condition of the Free and Cued Selective Reminding Test (Srtfree;
r = 0.53, p = 0.002), with the total correct score from the Animal Naming test (ANIMALS; r =
0.50, p = 0.0025), and with the Trailmaking Test Part A completion time (Tma; r = -0.47, p >
0.017). The decrease of R2t* is related to the neuronal damage in the hippocampus and so
corresponds to a bad cognitive performance. But R2t* in the cortex doesn’t significantly
correlate with these three cognitive tests. This may be because the participants were
characterized either as cognitively normal or having mild cognitive impairment (MCI), the
neuronal damage (decreased R2t*) occurs first in the hippocampal area but may not spread to the
cortical areas yet.

Figure 4.4 Correlation between cognitive tests performance and hippocampal R2t*. Cognitive
measures included Free and Cued Selective Reminding Test (Srtfree), Animal Naming
(ANIMALS), and Trail making Test Part A completion time (Tma). Note that higher scores on
Tma indicate worse performance. Correlations with hippocampal volume are also presented for
comparison. Each point represents a single participant (n = 34). Shaded areas represent 95%
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confidence intervals of linear fits (solid lines). Pearson correlation coefficients (r) and p values
are shown in the left upper corners.
Note that considerably weaker correlations were found between hippocampal volume and
cognitive performance (Figure 4.4, second column), suggesting that the integrity of the
remaining hippocampal tissue (characterized by R2t*) is a more important parameter of
hippocampal pathology than hippocampal volume.
No significant correlation was found between cognitive performance and R2* or CSF Aβ42. This
result is in agreement with the dissociation between PiB defined Aβ plaques and cognitive
performance (124-128). At least 30% of people with significant Aβ burden are cognitively
normal (124).

4.3.4 R2t* Distinguishes Cognitively Normal Group from Mild AD Group
Figure 4.5 shows examples of three participants’ GEPCI images from healthy control, preclinical
and mild AD groups. Thin contours outline the hippocampus determined by FreeSurfer. In all
cases, MPRAGE and GEPCI T1w images show small atrophy progressing from healthy to AD
group. Gradually decreased R2t* suggest altered tissue integrity even in the preserved
hippocampal area. One should keep in mind that GEPCI metrics (R2* and R2t*) are quantitative
and provide information on tissue integrity based on comparison with healthy control
measurements, thus uncovering tissue damage that might not be simply visible on images.
Though tissue damage in the hippocampus can be clearly seen as hypointense signal on R2t*
maps.
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Figure 4.5 Examples of three participants’ images – 69 year old female from the control group
(upper row), 72 year old male from the preclinical AD group (second row) and 69 year old male
from the mild AD (CDR = 0.5) group. Thin contours outline the hippocampus determined by
FreeSurfer. In all cases, MPRAGE and GEPCI T1w images show small atrophy progressing
from healthy to AD group. Gradually decreased GEPCI R2t* suggest altered tissue integrity even
in the preserved hippocampal area.

The bar graphs in Figure 4.6 show group comparisons based on R2t* in the hippocampus. Three
groups are shown - normal participants (CDR = 0, Aβ negative), preclinical group (CDR = 0, Aβ
positive) and mild AD (CDR = 0.5 or 1). The first box shows results for tissue R2t* and the
second block shows results for hippocampal volume. The significantly decreased hippocampal
volume in mild AD group is in agreement with known brain atrophy characteristic for AD (109).
While changes in R2t* likely reflect changes in the neuronal and synaptic density, it may also
reflect changes in other tissue components. Hypothetically, the slight but not significant increase
in tissue R2t* seen in preclinical group as compared to normal participants in Figure 4.6 and
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Table 4.3 may be attributed to accumulation of tau protein as in early Braak stages (105) of AD.
Interestingly, Figure 4.6 and Table 4.3 also show that the hippocampal volume in the preclinical
group was also slightly but not significantly higher than that in the normal group.

Figure 4.6 Bar graphs show the data obtained in the hippocampus of 34 participants. Bars
represent mean values and error bars are standard deviations. Data are separated into three
groups: Normal, preclinical AD, and mild AD (CDR 0.5 or 1). GEPCI R2t*, and volumes are
shown. Also shown is the parameter TCI (tissue content index, Equation (4.3)). While R2t* can
serve as a surrogate marker of neuronal density/integrity, the TCI can serve as a surrogate marker
characterizing a change in the total neuronal content. The results are summarized in Table 4.3.

-1

Normal
Preclinical
Mild AD

R2t*(s )
11.71 ± 1.45
12.20 ± 1.50
9.94 ± 1.38

Table 4.3
Volume(mm3)
3512 ± 327
3720 ± 452
2849 ± 552

TCI
0.00 ± 0.16
0.11 ± 0.22
-0.31 ± 0.16

Table 4.3. The mean and standard deviations of R2t*, volume and TCI in hippocampus over
three groups presented in Figure 4.6.
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If R2t* is related to neuronal density/integrity, the product of R2t* and the hippocampal volume
(V) could characterize the total neuronal content in the hippocampus. Hence, to characterize the
global tissue change in the hippocampus, it is convenient to introduce the Tissue Content Index
(TCI):
TCI 

(V  R 2t * )  (V  R2t * )control
(V  R 2t * )control

(4.3)

where (V  R2t )control = 41201 mm3·sec-1 is a mean value of tissue content in the group of
*

normal participants. The changes in the TCI between Normal, Preclinical and AD groups are
shown in the third box of Figure 4.6.
The results in Figure 4.6 show that not only does the hippocampal tissue volume reduce in mild
AD participants, but R2t* also reduces. As a result, the TCI reduce even more significantly.
These results are in a full agreement with the histopathological studies of Price, Morris and coworkers (59) who found that 46% of neurons were lost in the hippocampus of people with CDR
= 0.5 as compared to cognitively normal participants, while the hippocampal volume loss was
only 29%. Comparison of our findings with direct neuronal measurements in (59) further
confirms our hypothesized relationship between R2t* and neuronal density. The decreased R2t*
and TCI is consistent with decreased tissue neuronal density and the tissue neuronal content in
the hippocampus. Furthermore, no significant differences in hippocampal R2t*, volume and TCI
between the normal and preclinical AD groups, is also consistent with Price, Morris and coworkers’ finding of no significant difference in hippocampal neuron number and volume
between the normal and preclinical AD groups (59).
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4.4 Summary
In this study, we have demonstrated that the GEPCI technique provides a new approach to the in
vivo evaluation of pathology in the preclinical and early symptomatic stages of AD. It is based
on a multi-gradient-echo MRI sequence that is available from most MRI manufacturers. GEPCI
data are quantitative, reproducible and MRI scanner independent, thus allowing multi-center
applications. The results show that GEPCI metrics are good correlates of Aβ accumulation and
neurodegeneration. They are sensitive enough to distinguish between normal individuals and
those with preclinical (asymptomatic) and early symptomatic AD.
One of the significant conclusions of this study is that the tissue cellular integrity of the
preserved part of the hippocampus is a more important parameter affecting cognitive
performance than the hippocampal atrophy. This points out to the presence of significant
cognitive reserve in the hippocampal structure. Another important finding is that the AD
symptoms do not start until there has been significant cellular loss in the hippocampus identified
by GEPCI metrics, consistent with Price, Morris and colleagues (59).
Since MRI is a much more available modality than PET (current imaging “gold standard” for in
vivo quantifying AD (Aβ) brain pathology), and poses fewer risks, GEPCI metrics (R2* and
R2t*) have a potential for improving the quality of AD diagnostic measures, and the evaluation
of new disease-modifying therapies.
The results of this study are based on data obtained from 34 participants. Larger and independent
samples certainly should be used to further validate our findings.
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Chapter 5: Future Plan
Last but not least, the GEPCI approach has been used to study many cognitive disease. For
example, GEPCI has been used to identify brain tissue damage in multiple sclerosis (2, 4, 69-72)
and psychiatric diseases (73). R2* has been found to be significantly lower in patients with
multiple sclerosis (MS) than in healthy participants (2, 4, 69-72). Significant correlations
between age-adjusted R2* and clinical scores of MS have been reported for cortical regions (71).
Significant group effects based on GEPCI metrics have been observed in the superior temporal
cortex and in the thalamus of the participants with schizophrenia and bipolar disorder (73). In
this dissertation, the GEPCI approach has been applied to normal aging and Alzheimer’s disease.
Thus, there is a potential for the GEPCI approach to provide insightful information about
cognitive disease. Certainly, more experimental data should be investigated to validate this
approach. The following ideas may be considered as future directions:
1. More participants with various amounts of amyloid deposition should be recruited to
further validate the correlation between the PET biomarker retention of amyloid
deposition and GEPCI R2*.
2. More participants with CDR = 0, 0.5, and 1 should be recruited to further validate the
correlation between the cognitive performance tests and the GEPCI hippocampal R2t*,
and to further validate the ability of R2t* to distinguish cognitively normal and mild AD
groups.
3. A recent study reports the detection of tau deposition in vivo using PET imaging (54).
Similar correlations between PET biomarker retentions of tau and GEPCI metrics (e.g.,
R2* and R2t*) should be investigated.
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4. Examine the autopsy of participants who underwent GEPCI MRI prior to expiration.
Also investigate the histological results and GEPCI results. For example, investigate the
relationship between neuronal density and GEPCI R2t*.
5. Interestingly, supervised machine-learning classification and cross-validation algorithms
may be applied to quantitative GEPCI measurements to classify volunteers’ condition
with respect to Alzheimer’s disease if a large dataset is available. Because deep learning
has been widely used in image processing, it is interesting to apply deep-learning
algorithms directly to MRI images for classification.
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